AB 3059: Human milk.
- Session Year: 2023-2024
- House: Assembly
- Latest Version Date: 2024-09-29
Current Status:
Passed
(2024-09-29: Chaptered by Secretary of State - Chapter 975, Statutes of 2024.)
Introduced
In Committee
First Chamber
In Committee
Second Chamber
Enacted
Existing law licenses and regulates tissue banks and generally makes a violation of the requirements applicable to tissue banks a crime.
This bill would specify that a general acute care hospital is not required to have a license to operate a tissue bank to store or distribute pasteurized donor human milk that was obtained from a tissue bank licensed by the State Department of Public Health. The bill would exempt from licensing requirements a hospital storing or distributing human milk obtained from a licensed tissue bank. The bill would require hospitals that collect, process, store, or distribute human milk in any other circumstance to obtain a tissue bank license. To the extent that the bill would expand the class of hospitals subject to tissue bank licensing requirements, thereby expanding a crime, the bill would impose a state-mandated local program.
Existing law, the Knox-Keene Health Care Service Plan Act of 1975, requires the Department of Managed Health Care to license and regulate health care service plans and makes a willful violation of the act a crime. Other existing law requires the Department of Insurance to regulate health insurers. Existing law requires health care service plans and health insurers, as specified, to provide certain health benefits and services, including, among others, maternity hospital stays, inpatient hospital and ambulatory maternity services, and maternal mental health programs. Existing law generally requires a health care service plan or health insurance policy to provide an enrollee or insured with basic health care services, as specified.
This bill would include, in the above-described basic health care services, medically necessary pasteurized donor human milk obtained from a tissue bank licensed by the State Department of Public Health.
Because a violation of the bills provisions by a health care service plan would be a crime, the bill would impose a state-mandated local program.
The California Constitution requires the state to reimburse local agencies and school districts for certain costs mandated by the state. Statutory provisions establish procedures for making that reimbursement.
This bill would provide that no reimbursement is required by this act for a specified reason.
Existing law licenses and regulates tissue banks and generally makes a violation of the requirements applicable to tissue banks a crime.
This bill would specify that a general acute care hospital is not required to have a license to operate a tissue bank to store or distribute pasteurized donor human milk that was obtained from a tissue bank licensed by the State Department of Public Health. The bill would exempt from licensing requirements a hospital storing or distributing human milk obtained from a licensed tissue bank. The bill would require hospitals that collect, process, store, or distribute human milk in any other circumstance to obtain a tissue bank license. To the extent that the bill would expand the class of hospitals subject to tissue bank licensing requirements, thereby expanding a crime, the bill would impose a state-mandated local program.
Existing law, the Knox-Keene Health Care Service Plan Act of 1975, requires the Department of Managed Health Care to license and regulate health care service plans and makes a willful violation of the act a crime. Other existing law requires the Department of Insurance to regulate health insurers. Existing law requires health care service plans and health insurers, as specified, to provide certain health benefits and services, including, among others, maternity hospital stays, inpatient hospital and ambulatory maternity services, and maternal mental health programs. Existing law generally requires a health care service plan or health insurance policy to provide an enrollee or insured with basic health care services, as specified.
This bill would include, in the above-described basic health care services, medically necessary pasteurized donor human milk obtained from a tissue bank licensed by the State Department of Public Health.
Because a violation of the bills provisions by a health care service plan would be a crime, the bill would impose a state-mandated local program.
The California Constitution requires the state to reimburse local agencies and school districts for certain costs mandated by the state. Statutory provisions establish procedures for making that reimbursement.
This bill would provide that no reimbursement is required by this act for a specified reason.
Existing law licenses and regulates tissue banks and generally makes a violation of the requirements applicable to tissue banks a crime.
This bill would specify that a general acute care hospital is not required to have a license to operate a tissue bank to store or distribute pasteurized donor human milk that was obtained from a tissue bank licensed by the State Department of Public Health. The bill would exempt from licensing requirements a hospital storing or distributing human milk obtained from a licensed tissue bank. The bill would require hospitals that collect, process, store, or distribute human milk in any other circumstance to obtain a tissue bank license. To the extent that the bill would expand the class of hospitals subject to tissue bank licensing requirements, thereby expanding a crime, the bill would impose a state-mandated local program.
Existing law, the Knox-Keene Health Care Service Plan Act of 1975, requires the Department of Managed Health Care to license and regulate health care service plans and makes a willful violation of the act a crime. Other existing law requires the Department of Insurance to regulate health insurers. Existing law requires health care service plans and health insurers, as specified, to provide certain health benefits and services, including, among others, maternity hospital stays, inpatient hospital and ambulatory maternity services, and maternal mental health programs. Existing law generally requires a health care service plan or health insurance policy to provide an enrollee or insured with basic health care services, as specified.
This bill would require a health care service plan contract or health insurance policy that is issued, amended, delivered, or renewed on or after January 1, 2025, to cover include, in the above-described basic health care services, medically necessary pasteurized donor human milk obtained from a tissue bank licensed by the State Department of Public Health.
Because a violation of the bills provisions by a health care service plan would be a crime, the bill would impose a state-mandated local program.
The California Constitution requires the state to reimburse local agencies and school districts for certain costs mandated by the state. Statutory provisions establish procedures for making that reimbursement.
This bill would provide that no reimbursement is required by this act for a specified reason.
Existing law licenses and regulates tissue banks and generally makes a violation of the requirements applicable to tissue banks a crime. Existing law exempts a mothers milk bank, as defined, from paying a licensing fee to be a tissue bank.
This bill would specify that a general acute care hospital is not required to have a license to operate a tissue bank to store or distribute pasteurized donor human milk that was obtained from a mothers milk bank. tissue bank licensed by the State Department of Public Health.
Existing law, the Knox-Keene Health Care Service Plan Act of 1975, requires the Department of Managed Health Care to license and regulate health care service plans and makes a willful violation of the act a crime. Other existing law requires the Department of Insurance to regulate health insurers. Existing law requires health care service plans and health insurers, as specified, to provide certain health benefits and services, including, among others, maternity hospital stays, inpatient hospital and ambulatory maternity services, and maternal mental health programs.
This bill would require a health care service plan contract or health insurance policy that is issued, amended, delivered, or renewed on or after January 1, 2025, to cover the same health benefits for human milk and human milk derivatives covered under the Medi-Cal program as of 1988. medically necessary pasteurized donor human milk obtained from a tissue bank licensed by the State Department of Public Health.
Because a violation of the bills provisions by a health care service plan would be a crime, the bill would impose a state-mandated local program.
The California Constitution requires the state to reimburse local agencies and school districts for certain costs mandated by the state. Statutory provisions establish procedures for making that reimbursement.
This bill would provide that no reimbursement is required by this act for a specified reason.
Existing law licenses and regulates tissue banks and generally makes a violation of the requirements applicable to tissue banks a crime. Existing law exempts a mothers milk bank, as defined, from paying a licensing fee to be a tissue bank.
This bill would specify that a general acute care hospital is not required to have a license to operate a tissue bank to store or distribute pasteurized human milk that was obtained from a mothers milk bank.
Existing law, the Knox-Keene Health Care Service Plan Act of 1975, requires the Department of Managed Health Care to license and regulate health care service plans and makes a willful violation of the act a crime. Other existing law requires the Department of Insurance to regulate health insurers. Existing law requires an individual or small group health care service plan contract or health insurance policy issued, amended, or renewed on or after January 1, 2017, to include, at a minimum, coverage for essential health benefits pursuant to the federal Patient Protection and Affordable Care Act. Under existing law, essential health benefits include, among other things, certain maternity and newborn care. health care service plans and health insurers, as specified, to provide certain health benefits and services, including, among others, maternity hospital stays, inpatient hospital and ambulatory maternity services, and maternal mental health programs.
This bill would specify that coverage of essential health benefits under a health care service plan or health insurance policy includes, with respect to maternity and newborn care, require a health care service plan contract or health insurance policy that is issued, amended, delivered, or renewed on or after January 1, 2025, to cover the same health benefits for human milk and human milk derivatives covered under the Medi-Cal program as of 1988.
Because a violation of the bills provisions by a health care service plan would be a crime, the bill would impose a state-mandated local program.
The California Constitution requires the state to reimburse local agencies and school districts for certain costs mandated by the state. Statutory provisions establish procedures for making that reimbursement.
This bill would provide that no reimbursement is required by this act for a specified reason.
Existing law licenses and regulates tissue banks and generally makes a violation of the requirements applicable to tissue banks a crime. Existing law exempts a mothers milk bank, as defined, from paying a licensing fee to be a tissue bank.
This bill would specify that a general acute care hospital is not required to have a license to operate a tissue bank to store or distribute pasteurized human milk that was obtained from a mothers milk bank.
Existing law, the Knox-Keene Health Care Service Plan Act of 1975, requires the Department of Managed Health Care to license and regulate health care service plans and makes a willful violation of the act a crime. Other existing law requires the Department of Insurance to regulate health insurers. Existing law requires an individual or small group health care service plan contract or health insurance policy issued, amended, or renewed on or after January 1, 2017, to include, at a minimum, coverage for essential health benefits pursuant to the federal Patient Protection and Affordable Care Act. Under existing law, essential health benefits include, among other things, certain maternity and newborn care.
This bill would specify that coverage of essential health benefits under a health care service plan or health insurance policy includes, with respect to maternity and newborn care, the same health benefits for human milk and human milk derivatives covered under the Medi-Cal program as of 1988.
Because a violation of the bills provisions by a health care service plan would be a crime, the bill would impose a state-mandated local program.
The California Constitution requires the state to reimburse local agencies and school districts for certain costs mandated by the state. Statutory provisions establish procedures for making that reimbursement.
This bill would provide that no reimbursement is required by this act for a specified reason.
The provision of medically necessary pasteurized donor human milk obtained from a tissue bank licensed pursuant to Chapter 4.1 (commencing with Section 1635) is a basic health care service, as defined in subdivision (b) of Section 1345 and any regulations adopted thereunder.
SEC. 2.Section 1635.1 of the Health and Safety Code is amended to read:1635.1.(a)Except as provided in subdivision (b), every tissue bank operating in California on or after July 1, 1992, shall have a current and valid tissue bank license issued or renewed by the department pursuant to Section 1639.2 or 1639.3.
(b)This chapter does not apply to any of the following:
(1)The collection, processing, storage, or distribution of human whole blood or its derivatives by blood banks licensed pursuant to Chapter 4 (commencing with Section 1600) or any person exempt from licensure under that chapter.
(2)The collection, processing, storage, or distribution of tissue for autopsy, biopsy, training, education, or for other medical or scientific research or investigation, when transplantation of the tissue is not intended or reasonably foreseeable.
(3)The collection of tissue by an individual physician and surgeon from their patient or the implantation of tissue by an individual physician and surgeon into their patient. This exemption shall not be interpreted to apply to any processing or storage of the tissue, except for the processing and storage of semen by an individual physician and surgeon when the semen was collected by that physician and surgeon from a semen donor or obtained by that physician and surgeon from a tissue bank licensed under this chapter.
(4)The collection, processing, storage, or distribution of fetal tissue or tissue derived from a human embryo or fetus.
(5)The collection, processing, storage, or distribution by an organ procurement organization (OPO), as defined in Section 486.302 of Title 42 of the Code of Federal Regulations, if the OPO, at the time of collection, processing, storage, and distribution of the tissue, has been designated by the Secretary of Health and Human Services as an OPO and meets the requirements of Sections 486.304 and 486.306 of Title 42 of the Code of Federal Regulations, as applicable.
(6)The storage of prepackaged, freeze-dried bone by a general acute care hospital.
(7)The storage of freeze-dried bone and dermis by any licensed dentist practicing in a lawful practice setting, if the freeze-dried bone and dermis have been obtained from a licensed tissue bank, are stored in strict accordance with a kits package insert and any other manufacturer instructions and guidelines, and are used for the express purpose of implantation into a patient.
(8)The storage of a human cell, tissue, or cellular- or tissue-based product (HCT/P), as defined by the federal Food and Drug Administration (FDA), that is either a medical device approved pursuant to Section 510 or 515 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. Sec. 360 et seq.) or that is a biologic product approved under Section 351 of the federal Public Health Service Act (42 U.S.C. Sec. 262) by a licensed physician or podiatrist acting within the scope and authority of their license and practicing in a lawful practice setting. The medical device or biologic product must have been obtained from a California-licensed tissue bank, been stored in strict accordance with the devices or products package insert and any other manufacturer instructions, and used solely for the express purpose of direct implantation into or application on the practitioners own patient. In order to be eligible for the exemption in this paragraph, the entity or organization where the physician or podiatrist who is eligible for the exemption is practicing shall notify the department, in writing, that the practitioner is licensed and meets the requirements of this paragraph. The notification shall include all of the following:
(A)A list of all practitioners to whom the notice applies.
(B)Acknowledgment that each listed practitioner uses the medical device or biologic product in the scope and authority of their license and practice for the purposes of direct patient care as described in this paragraph.
(C)A statement that each listed practitioner agrees to strictly abide by the directions for storage in the devices or products package insert and any other manufacturer instructions and guidelines.
(D)Acknowledgment by each practitioner that the medical device or biologic product shall not be resold or distributed.
(9)The collection, processing, storage, or distribution of any organ, as defined in paragraph (2) of subdivision (c) of Section 1635, within a single general acute care hospital, as defined in subdivision (a) of Section 1250, operating a Medicare-approved transplant program.
(10)The storage of allograft tissue by a person if all of the following apply:
(A)The person, as defined in Section 1635, is a hospital, or an outpatient setting regulated by the Medical Board of California pursuant to Chapter 1.3 (commencing with Section 1248), including an ambulatory surgical center.
(B)The person maintains a log that includes the date on which the allograft tissue was received, the expiration date of the allograft tissue, the date on which each allograft tissue is used for clinical purposes, and the disposition of any allograft tissue samples that remain unused at the time the allograft tissue expires.
(C)The allograft tissue meets all of the following:
(i)The allograft tissue was obtained from a tissue bank licensed by the state.
(ii)Each allograft tissue is individually boxed and labeled with a unique identification number and expiration date so that opening the shipping container will not disturb or otherwise alter any of the allograft tissue that is not being utilized.
(iii)The allograft tissue is intended for the express purpose of implantation into or application on a patient.
(iv)The allograft tissue is not intended for further distribution.
(v)The allograft tissue is registered with the FDA and designated to be maintained at ambient room temperature requiring no refrigeration.
(11)The storage or preparation for patient administration of tissue performed at a clinical trial site that is intended solely for investigational use by experts qualified by scientific training and experience to investigate the safety and effectiveness of drugs or devices if the investigation is conducted in accordance with the requirements of Section 505(i) of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. Sec. 355(i)) or Section 520(g) thereof (21 U.S.C. Sec. 360j(g)) and the regulations adopted pursuant to the federal act.
(12)The storage or distribution of pasteurized donor human milk that was obtained from a tissue bank, licensed pursuant to this chapter, by a general acute care hospital. A general acute care hospital that is exempt from licensure as a tissue bank pursuant to this paragraph shall comply with the requirements of subdivision (b) of Section 1648.
SEC. 3.Section 1648 of the Health and Safety Code is amended to read:1648.(a)A hospital collecting, processing, storing, or distributing human milk collected from a mother exclusively for the mothers own child, or a hospital storing or distributing human milk obtained from a tissue bank that is licensed pursuant to Chapter 4.1 (commencing with Section 1635), is exempt from the requirements of Chapter 4.1 (commencing with Section 1635). Hospitals that collect, process, store, or distribute human milk in any other circumstance shall obtain a tissue bank license pursuant to Chapter 4.1 (commencing with Section 1635).
(b)A hospital that is exempt from tissue bank licensure pursuant to subdivision (a) shall comply with the most current standards established for the collection, processing, storage, or distribution of human milk by the Human Milk Banking Association of North America or other standards approved by the department.
(c)Notwithstanding any other provision of law, no screening tests shall be required to be performed on human milk collected from a mother exclusively for the mothers own child.
(d)The department shall assess hospital processes for collecting, processing, storing, or distributing human milk pursuant to its current practice, as required by Chapter 2 (commencing with Section 1250).
SEC. 4.Section 10123.864 is added to the Insurance Code, to read:10123.864.The provision of medically necessary pasteurized donor human milk obtained from a tissue bank licensed pursuant to Chapter 4.1 (commencing with Section 1635) of Division 2 of the Health and Safety Code is a basic health care service, as described in Sections 10112.27 and 10112.281 and any regulations adopted thereunder.
SEC. 5.No reimbursement is required by this act pursuant to Section 6 of Article XIIIB of the California Constitution because the only costs that may be incurred by a local agency or school district will be incurred because this act creates a new crime or infraction, eliminates a crime or infraction, or changes the penalty for a crime or infraction, within the meaning of Section 17556 of the Government Code, or changes the definition of a crime within the meaning of Section 6 of Article XIIIB of the California Constitution.
The provision of medically necessary pasteurized donor human milk obtained from a tissue bank licensed pursuant to Chapter 4.1 (commencing with Section 1635) is a basic health care service, as defined in subdivision (b) of Section 1345 and any regulations adopted thereunder.
SEC. 2.Section 1635.1 of the Health and Safety Code is amended to read:1635.1.(a)Except as provided in subdivision (b), every tissue bank operating in California on or after July 1, 1992, shall have a current and valid tissue bank license issued or renewed by the department pursuant to Section 1639.2 or 1639.3.
(b)This chapter does not apply to any of the following:
(1)The collection, processing, storage, or distribution of human whole blood or its derivatives by blood banks licensed pursuant to Chapter 4 (commencing with Section 1600) or any person exempt from licensure under that chapter.
(2)The collection, processing, storage, or distribution of tissue for autopsy, biopsy, training, education, or for other medical or scientific research or investigation, when transplantation of the tissue is not intended or reasonably foreseeable.
(3)The collection of tissue by an individual physician and surgeon from their patient or the implantation of tissue by an individual physician and surgeon into their patient. This exemption shall not be interpreted to apply to any processing or storage of the tissue, except for the processing and storage of semen by an individual physician and surgeon when the semen was collected by that physician and surgeon from a semen donor or obtained by that physician and surgeon from a tissue bank licensed under this chapter.
(4)The collection, processing, storage, or distribution of fetal tissue or tissue derived from a human embryo or fetus.
(5)The collection, processing, storage, or distribution by an organ procurement organization (OPO), as defined in Section 486.302 of Title 42 of the Code of Federal Regulations, if the OPO, at the time of collection, processing, storage, and distribution of the tissue, has been designated by the Secretary of Health and Human Services as an OPO and meets the requirements of Sections 486.304 and 486.306 of Title 42 of the Code of Federal Regulations, as applicable.
(6)The storage of prepackaged, freeze-dried bone by a general acute care hospital.
(7)The storage of freeze-dried bone and dermis by any licensed dentist practicing in a lawful practice setting, if the freeze-dried bone and dermis have been obtained from a licensed tissue bank, are stored in strict accordance with a kits package insert and any other manufacturer instructions and guidelines, and are used for the express purpose of implantation into a patient.
(8)The storage of a human cell, tissue, or cellular- or tissue-based product (HCT/P), as defined by the federal Food and Drug Administration (FDA), that is either a medical device approved pursuant to Section 510 or 515 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. Sec. 360 et seq.) or that is a biologic product approved under Section 351 of the federal Public Health Service Act (42 U.S.C. Sec. 262) by a licensed physician or podiatrist acting within the scope and authority of their license and practicing in a lawful practice setting. The medical device or biologic product must have been obtained from a California-licensed tissue bank, been stored in strict accordance with the devices or products package insert and any other manufacturer instructions, and used solely for the express purpose of direct implantation into or application on the practitioners own patient. In order to be eligible for the exemption in this paragraph, the entity or organization where the physician or podiatrist who is eligible for the exemption is practicing shall notify the department, in writing, that the practitioner is licensed and meets the requirements of this paragraph. The notification shall include all of the following:
(A)A list of all practitioners to whom the notice applies.
(B)Acknowledgment that each listed practitioner uses the medical device or biologic product in the scope and authority of their license and practice for the purposes of direct patient care as described in this paragraph.
(C)A statement that each listed practitioner agrees to strictly abide by the directions for storage in the devices or products package insert and any other manufacturer instructions and guidelines.
(D)Acknowledgment by each practitioner that the medical device or biologic product shall not be resold or distributed.
(9)The collection, processing, storage, or distribution of any organ, as defined in paragraph (2) of subdivision (c) of Section 1635, within a single general acute care hospital, as defined in subdivision (a) of Section 1250, operating a Medicare-approved transplant program.
(10)The storage of allograft tissue by a person if all of the following apply:
(A)The person, as defined in Section 1635, is a hospital, or an outpatient setting regulated by the Medical Board of California pursuant to Chapter 1.3 (commencing with Section 1248), including an ambulatory surgical center.
(B)The person maintains a log that includes the date on which the allograft tissue was received, the expiration date of the allograft tissue, the date on which each allograft tissue is used for clinical purposes, and the disposition of any allograft tissue samples that remain unused at the time the allograft tissue expires.
(C)The allograft tissue meets all of the following:
(i)The allograft tissue was obtained from a tissue bank licensed by the state.
(ii)Each allograft tissue is individually boxed and labeled with a unique identification number and expiration date so that opening the shipping container will not disturb or otherwise alter any of the allograft tissue that is not being utilized.
(iii)The allograft tissue is intended for the express purpose of implantation into or application on a patient.
(iv)The allograft tissue is not intended for further distribution.
(v)The allograft tissue is registered with the FDA and designated to be maintained at ambient room temperature requiring no refrigeration.
(11)The storage or preparation for patient administration of tissue performed at a clinical trial site that is intended solely for investigational use by experts qualified by scientific training and experience to investigate the safety and effectiveness of drugs or devices if the investigation is conducted in accordance with the requirements of Section 505(i) of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. Sec. 355(i)) or Section 520(g) thereof (21 U.S.C. Sec. 360j(g)) and the regulations adopted pursuant to the federal act.
(12)The storage or distribution of pasteurized donor human milk that was obtained from a tissue bank, licensed pursuant to this chapter, by a general acute care hospital. A general acute care hospital that is exempt from licensure as a tissue bank pursuant to this paragraph shall comply with the requirements of subdivision (b) of Section 1648.
SEC. 3.Section 1648 of the Health and Safety Code is amended to read:1648.(a)A hospital collecting, processing, storing, or distributing human milk collected from a mother exclusively for the mothers own child, or a hospital storing or distributing human milk obtained from a tissue bank that is licensed pursuant to Chapter 4.1 (commencing with Section 1635), is exempt from the requirements of Chapter 4.1 (commencing with Section 1635). Hospitals that collect, process, store, or distribute human milk in any other circumstance shall obtain a tissue bank license pursuant to Chapter 4.1 (commencing with Section 1635).
(b)A hospital that is exempt from tissue bank licensure pursuant to subdivision (a) shall comply with the most current standards established for the collection, processing, storage, or distribution of human milk by the Human Milk Banking Association of North America or other standards approved by the department.
(c)Notwithstanding any other provision of law, no screening tests shall be required to be performed on human milk collected from a mother exclusively for the mothers own child.
(d)The department shall assess hospital processes for collecting, processing, storing, or distributing human milk pursuant to its current practice, as required by Chapter 2 (commencing with Section 1250).
SEC. 4.Section 10123.864 is added to the Insurance Code, to read:10123.864.The provision of medically necessary pasteurized donor human milk obtained from a tissue bank licensed pursuant to Chapter 4.1 (commencing with Section 1635) of Division 2 of the Health and Safety Code is a basic health care service, as described in Sections 10112.27 and 10112.281 and any regulations adopted thereunder.
SEC. 5.No reimbursement is required by this act pursuant to Section 6 of Article XIIIB of the California Constitution because the only costs that may be incurred by a local agency or school district will be incurred because this act creates a new crime or infraction, eliminates a crime or infraction, or changes the penalty for a crime or infraction, within the meaning of Section 17556 of the Government Code, or changes the definition of a crime within the meaning of Section 6 of Article XIIIB of the California Constitution.
A health care service plan contract, except for a specialized health care service plan contract, that is issued, amended, delivered, or renewed on or after January 1, 2025, shall cover The provision of medically necessary pasteurized donor human milk obtained from a tissue bank licensed pursuant to subdivision (a) of Section 1635.1. Chapter 4.1 (commencing with Section 1635) is a basic health care service, as defined in subdivision (b) of Section 1345 and any regulations adopted thereunder.
SEC. 2.Section 1635.1 of the Health and Safety Code is amended to read:1635.1.(a)Except as provided in subdivision (b), every tissue bank operating in California on or after July 1, 1992, shall have a current and valid tissue bank license issued or renewed by the department pursuant to Section 1639.2 or 1639.3.
(b)This chapter does not apply to any of the following:
(1)The collection, processing, storage, or distribution of human whole blood or its derivatives by blood banks licensed pursuant to Chapter 4 (commencing with Section 1600) or any person exempt from licensure under that chapter.
(2)The collection, processing, storage, or distribution of tissue for autopsy, biopsy, training, education, or for other medical or scientific research or investigation, when transplantation of the tissue is not intended or reasonably foreseeable.
(3)The collection of tissue by an individual physician and surgeon from their patient or the implantation of tissue by an individual physician and surgeon into their patient. This exemption shall not be interpreted to apply to any processing or storage of the tissue, except for the processing and storage of semen by an individual physician and surgeon when the semen was collected by that physician and surgeon from a semen donor or obtained by that physician and surgeon from a tissue bank licensed under this chapter.
(4)The collection, processing, storage, or distribution of fetal tissue or tissue derived from a human embryo or fetus.
(5)The collection, processing, storage, or distribution by an organ procurement organization (OPO), as defined in Section 486.302 of Title 42 of the Code of Federal Regulations, if the OPO, at the time of collection, processing, storage, and distribution of the tissue, has been designated by the Secretary of Health and Human Services as an OPO and meets the requirements of Sections 486.304 and 486.306 of Title 42 of the Code of Federal Regulations, as applicable.
(6)The storage of prepackaged, freeze-dried bone by a general acute care hospital.
(7)The storage of freeze-dried bone and dermis by any licensed dentist practicing in a lawful practice setting, if the freeze-dried bone and dermis have been obtained from a licensed tissue bank, are stored in strict accordance with a kits package insert and any other manufacturer instructions and guidelines, and are used for the express purpose of implantation into a patient.
(8)The storage of a human cell, tissue, or cellular- or tissue-based product (HCT/P), as defined by the federal Food and Drug Administration (FDA), that is either a medical device approved pursuant to Section 510 or 515 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. Sec. 360 et seq.) or that is a biologic product approved under Section 351 of the federal Public Health Service Act (42 U.S.C. Sec. 262) by a licensed physician or podiatrist acting within the scope and authority of their license and practicing in a lawful practice setting. The medical device or biologic product must have been obtained from a California-licensed tissue bank, been stored in strict accordance with the devices or products package insert and any other manufacturer instructions, and used solely for the express purpose of direct implantation into or application on the practitioners own patient. In order to be eligible for the exemption in this paragraph, the entity or organization where the physician or podiatrist who is eligible for the exemption is practicing shall notify the department, in writing, that the practitioner is licensed and meets the requirements of this paragraph. The notification shall include all of the following:
(A)A list of all practitioners to whom the notice applies.
(B)Acknowledgment that each listed practitioner uses the medical device or biologic product in the scope and authority of their license and practice for the purposes of direct patient care as described in this paragraph.
(C)A statement that each listed practitioner agrees to strictly abide by the directions for storage in the devices or products package insert and any other manufacturer instructions and guidelines.
(D)Acknowledgment by each practitioner that the medical device or biologic product shall not be resold or distributed.
(9)The collection, processing, storage, or distribution of any organ, as defined in paragraph (2) of subdivision (c) of Section 1635, within a single general acute care hospital, as defined in subdivision (a) of Section 1250, operating a Medicare-approved transplant program.
(10)The storage of allograft tissue by a person if all of the following apply:
(A)The person, as defined in Section 1635, is a hospital, or an outpatient setting regulated by the Medical Board of California pursuant to Chapter 1.3 (commencing with Section 1248), including an ambulatory surgical center.
(B)The person maintains a log that includes the date on which the allograft tissue was received, the expiration date of the allograft tissue, the date on which each allograft tissue is used for clinical purposes, and the disposition of any allograft tissue samples that remain unused at the time the allograft tissue expires.
(C)The allograft tissue meets all of the following:
(i)The allograft tissue was obtained from a tissue bank licensed by the state.
(ii)Each allograft tissue is individually boxed and labeled with a unique identification number and expiration date so that opening the shipping container will not disturb or otherwise alter any of the allograft tissue that is not being utilized.
(iii)The allograft tissue is intended for the express purpose of implantation into or application on a patient.
(iv)The allograft tissue is not intended for further distribution.
(v)The allograft tissue is registered with the FDA and designated to be maintained at ambient room temperature requiring no refrigeration.
(11)The storage or preparation for patient administration of tissue performed at a clinical trial site that is intended solely for investigational use by experts qualified by scientific training and experience to investigate the safety and effectiveness of drugs or devices if the investigation is conducted in accordance with the requirements of Section 505(i) of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. Sec. 355(i)) or Section 520(g) thereof (21 U.S.C. Sec. 360j(g)) and the regulations adopted pursuant to the federal act.
(12)The storage or distribution of pasteurized donor human milk that was obtained from a tissue bank, licensed pursuant to subdivision (a) of Section 1635.1, this chapter, by a general acute care hospital. A general acute care hospital that is exempt from licensure as a tissue bank pursuant to this paragraph shall comply with the requirements of subdivision (b) of Section 1648.
SEC. 3.Section 1648 of the Health and Safety Code is amended to read:1648.(a)A hospital that collects, processes, stores, or distributes human milk collected from a mother exclusively for her own child shall comply with the most current standards established for the collection, processing, storage, or distribution of human milk by the Human Milk Banking Association of North America until or unless the department approves alternative standards.(b)1648.(a)A hospital shall be exempt from the requirements of Chapter 4.1 (commencing with Section 1635) for the purpose of collecting, processing, storing, or distributing human milk collected from a mother exclusively for her own child. the mothers own child, or a hospital storing or distributing human milk obtained from a tissue bank that is licensed pursuant to Chapter 4.1 (commencing with Section 1635), is exempt from the requirements of Chapter 4.1 (commencing with Section 1635). Hospitals that collect, process, store, or distribute human milk in any other circumstance shall obtain a tissue bank license pursuant to Chapter 4.1 (commencing with Section 1635).
(b)A hospital that is exempt from tissue bank licensure pursuant to subdivision (a) shall comply with the most current standards established for the collection, processing, storage, or distribution of human milk by the Human Milk Banking Association of North America or other standards approved by the department.
(c)Notwithstanding any other provision of law, no screening tests shall be required to be performed on human milk collected from a mother exclusively for her the mothers own child.
(d)The department shall assess hospital processes for collecting, processing, storing, or distributing human milk pursuant to its current practice, as required by Chapter 2 (commencing with Section 1250).
(e)This section does not apply to any hospital that collects, processes, stores, or distributes milk from human milk banks or other outside sources.SEC. 3.SEC. 4.Section 10123.864 is added to the Insurance Code, to read:10123.864.A health insurance policy, except a specialized health insurance policy, that is issued, amended, delivered, or renewed on or after January 1, 2025, shall cover The provision of medically necessary pasteurized donor human milk obtained from a tissue bank licensed pursuant to subdivision (a) of Section 1635.1 of the Health and Safety Code. Chapter 4.1 (commencing with Section 1635) of Division 2 of the Health and Safety Code is a basic health care service, as described in Sections 10112.27 and 10112.281 and any regulations adopted thereunder.
SEC. 4.SEC. 5.No reimbursement is required by this act pursuant to Section 6 of Article XIIIB of the California Constitution because the only costs that may be incurred by a local agency or school district will be incurred because this act creates a new crime or infraction, eliminates a crime or infraction, or changes the penalty for a crime or infraction, within the meaning of Section 17556 of the Government Code, or changes the definition of a crime within the meaning of Section 6 of Article XIIIB of the California Constitution.
A health care service plan contract, except for a specialized health care service plan contract, that is issued, amended, delivered, or renewed on or after January 1, 2025, shall cover the same health benefits for human milk and human milk derivatives covered under the Medi-Cal program as of 1988. medically necessary pasteurized donor human milk obtained from a tissue bank licensed pursuant to subdivision (a) of Section 1635.1.
SEC. 2.Section 1635.1 of the Health and Safety Code is amended to read:1635.1.(a)Except as provided in subdivision (b), every tissue bank operating in California on or after July 1, 1992, shall have a current and valid tissue bank license issued or renewed by the department pursuant to Section 1639.2 or 1639.3.
(b)This chapter does not apply to any of the following:
(1)The collection, processing, storage, or distribution of human whole blood or its derivatives by blood banks licensed pursuant to Chapter 4 (commencing with Section 1600) or any person exempt from licensure under that chapter.
(2)The collection, processing, storage, or distribution of tissue for autopsy, biopsy, training, education, or for other medical or scientific research or investigation, when transplantation of the tissue is not intended or reasonably foreseeable.
(3)The collection of tissue by an individual physician and surgeon from their patient or the implantation of tissue by an individual physician and surgeon into their patient. This exemption shall not be interpreted to apply to any processing or storage of the tissue, except for the processing and storage of semen by an individual physician and surgeon when the semen was collected by that physician and surgeon from a semen donor or obtained by that physician and surgeon from a tissue bank licensed under this chapter.
(4)The collection, processing, storage, or distribution of fetal tissue or tissue derived from a human embryo or fetus.
(5)The collection, processing, storage, or distribution by an organ procurement organization (OPO), as defined in Section 486.302 of Title 42 of the Code of Federal Regulations, if the OPO, at the time of collection, processing, storage, and distribution of the tissue, has been designated by the Secretary of Health and Human Services as an OPO and meets the requirements of Sections 486.304 and 486.306 of Title 42 of the Code of Federal Regulations, as applicable.
(6)The storage of prepackaged, freeze-dried bone by a general acute care hospital.
(7)The storage of freeze-dried bone and dermis by any licensed dentist practicing in a lawful practice setting, if the freeze-dried bone and dermis have been obtained from a licensed tissue bank, are stored in strict accordance with a kits package insert and any other manufacturer instructions and guidelines, and are used for the express purpose of implantation into a patient.
(8)The storage of a human cell, tissue, or cellular- or tissue-based product (HCT/P), as defined by the federal Food and Drug Administration (FDA), that is either a medical device approved pursuant to Section 510 or 515 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. Sec. 360 et seq.) or that is a biologic product approved under Section 351 of the federal Public Health Service Act (42 U.S.C. Sec. 262) by a licensed physician or podiatrist acting within the scope and authority of their license and practicing in a lawful practice setting. The medical device or biologic product must have been obtained from a California-licensed tissue bank, been stored in strict accordance with the devices or products package insert and any other manufacturer instructions, and used solely for the express purpose of direct implantation into or application on the practitioners own patient. In order to be eligible for the exemption in this paragraph, the entity or organization where the physician or podiatrist who is eligible for the exemption is practicing shall notify the department, in writing, that the practitioner is licensed and meets the requirements of this paragraph. The notification shall include all of the following:
(A)A list of all practitioners to whom the notice applies.
(B)Acknowledgment that each listed practitioner uses the medical device or biologic product in the scope and authority of their license and practice for the purposes of direct patient care as described in this paragraph.
(C)A statement that each listed practitioner agrees to strictly abide by the directions for storage in the devices or products package insert and any other manufacturer instructions and guidelines.
(D)Acknowledgment by each practitioner that the medical device or biologic product shall not be resold or distributed.
(9)The collection, processing, storage, or distribution of any organ, as defined in paragraph (2) of subdivision (c) of Section 1635, within a single general acute care hospital, as defined in subdivision (a) of Section 1250, operating a Medicare-approved transplant program.
(10)The storage of allograft tissue by a person if all of the following apply:
(A)The person, as defined in Section 1635, is a hospital, or an outpatient setting regulated by the Medical Board of California pursuant to Chapter 1.3 (commencing with Section 1248), including an ambulatory surgical center.
(B)The person maintains a log that includes the date on which the allograft tissue was received, the expiration date of the allograft tissue, the date on which each allograft tissue is used for clinical purposes, and the disposition of any allograft tissue samples that remain unused at the time the allograft tissue expires.
(C)The allograft tissue meets all of the following:
(i)The allograft tissue was obtained from a tissue bank licensed by the state.
(ii)Each allograft tissue is individually boxed and labeled with a unique identification number and expiration date so that opening the shipping container will not disturb or otherwise alter any of the allograft tissue that is not being utilized.
(iii)The allograft tissue is intended for the express purpose of implantation into or application on a patient.
(iv)The allograft tissue is not intended for further distribution.
(v)The allograft tissue is registered with the FDA and designated to be maintained at ambient room temperature requiring no refrigeration.
(11)The storage or preparation for patient administration of tissue performed at a clinical trial site that is intended solely for investigational use by experts qualified by scientific training and experience to investigate the safety and effectiveness of drugs or devices if the investigation is conducted in accordance with the requirements of Section 505(i) of the federal Federal Food, Drug, and Cosmetic Act (21 U.S.C. Sec. 355(i)) or Section 520(g) thereof (21 U.S.C. Sec. 360j(g)) and the regulations adopted pursuant to the federal act.
(12)The storage or distribution of pasteurized donor human milk that was obtained from a mothers milk bank, as defined in Section 14132.34 of the Welfare and Institutions Code, tissue bank, licensed pursuant to subdivision (a) of Section 1635.1, by a general acute care hospital.
SEC. 3.Section 10123.864 is added to the Insurance Code, to read:10123.864.A health insurance policy, except a specialized health insurance policy, that is issued, amended, delivered, or renewed on or after January 1, 2025, shall cover the same health benefits for human milk and human milk derivatives covered under the Medi-Cal program as of 1988. medically necessary pasteurized donor human milk obtained from a tissue bank licensed pursuant to subdivision (a) of Section 1635.1 of the Health and Safety Code.
SEC. 4.No reimbursement is required by this act pursuant to Section 6 of Article XIIIB of the California Constitution because the only costs that may be incurred by a local agency or school district will be incurred because this act creates a new crime or infraction, eliminates a crime or infraction, or changes the penalty for a crime or infraction, within the meaning of Section 17556 of the Government Code, or changes the definition of a crime within the meaning of Section 6 of Article XIIIB of the California Constitution.
A health care service plan contract, except for a specialized health care service plan contract, that is issued, amended, delivered, or renewed on or after January 1, 2025, shall cover the same health benefits for human milk and human milk derivatives covered under the Medi-Cal program as of 1988.
SEC. 2.Section 1635.1 of the Health and Safety Code is amended to read:1635.1.(a)Except as provided in subdivision (b), every tissue bank operating in California on or after July 1, 1992, shall have a current and valid tissue bank license issued or renewed by the department pursuant to Section 1639.2 or 1639.3.
(b)This chapter does not apply to any of the following:
(1)The collection, processing, storage, or distribution of human whole blood or its derivatives by blood banks licensed pursuant to Chapter 4 (commencing with Section 1600) or any person exempt from licensure under that chapter.
(2)The collection, processing, storage, or distribution of tissue for autopsy, biopsy, training, education, or for other medical or scientific research or investigation, when transplantation of the tissue is not intended or reasonably foreseeable.
(3)The collection of tissue by an individual physician and surgeon from their patient or the implantation of tissue by an individual physician and surgeon into their patient. This exemption shall not be interpreted to apply to any processing or storage of the tissue, except for the processing and storage of semen by an individual physician and surgeon when the semen was collected by that physician and surgeon from a semen donor or obtained by that physician and surgeon from a tissue bank licensed under this chapter.
(4)The collection, processing, storage, or distribution of fetal tissue or tissue derived from a human embryo or fetus.
(5)The collection, processing, storage, or distribution by an organ procurement organization (OPO), as defined in Section 486.302 of Title 42 of the Code of Federal Regulations, if the OPO, at the time of collection, processing, storage, and distribution of the tissue, has been designated by the Secretary of Health and Human Services as an OPO and meets the requirements of Sections 486.304 and 486.306 of Title 42 of the Code of Federal Regulations, as applicable.
(6)The storage of prepackaged, freeze-dried bone by a general acute care hospital.
(7)The storage of freeze-dried bone and dermis by any licensed dentist practicing in a lawful practice setting, if the freeze-dried bone and dermis have been obtained from a licensed tissue bank, are stored in strict accordance with a kits package insert and any other manufacturer instructions and guidelines, and are used for the express purpose of implantation into a patient.
(8)The storage of a human cell, tissue, or cellular- or tissue-based product (HCT/P), as defined by the federal Food and Drug Administration (FDA), that is either a medical device approved pursuant to Section 510 or 515 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. Sec. 360 et seq.) or that is a biologic product approved under Section 351 of the federal Public Health Service Act (42 U.S.C. Sec. 262) by a licensed physician or podiatrist acting within the scope and authority of their license and practicing in a lawful practice setting. The medical device or biologic product must have been obtained from a California-licensed tissue bank, been stored in strict accordance with the devices or products package insert and any other manufacturer instructions, and used solely for the express purpose of direct implantation into or application on the practitioners own patient. In order to be eligible for the exemption in this paragraph, the entity or organization where the physician or podiatrist who is eligible for the exemption is practicing shall notify the department, in writing, that the practitioner is licensed and meets the requirements of this paragraph. The notification shall include all of the following:
(A)A list of all practitioners to whom the notice applies.
(B)Acknowledgment that each listed practitioner uses the medical device or biologic product in the scope and authority of their license and practice for the purposes of direct patient care as described in this paragraph.
(C)A statement that each listed practitioner agrees to strictly abide by the directions for storage in the devices or products package insert and any other manufacturer instructions and guidelines.
(D)Acknowledgment by each practitioner that the medical device or biologic product shall not be resold or distributed.
(9)The collection, processing, storage, or distribution of any organ, as defined in paragraph (2) of subdivision (c) of Section 1635, within a single general acute care hospital, as defined in subdivision (a) of Section 1250, operating a Medicare-approved transplant program.
(10)The storage of allograft tissue by a person if all of the following apply:
(A)The person, as defined in Section 1635, is a hospital, or an outpatient setting regulated by the Medical Board of California pursuant to Chapter 1.3 (commencing with Section 1248), including an ambulatory surgical center.
(B)The person maintains a log that includes the date on which the allograft tissue was received, the expiration date of the allograft tissue, the date on which each allograft tissue is used for clinical purposes, and the disposition of any allograft tissue samples that remain unused at the time the allograft tissue expires.
(C)The allograft tissue meets all of the following:
(i)The allograft tissue was obtained from a tissue bank licensed by the state.
(ii)Each allograft tissue is individually boxed and labeled with a unique identification number and expiration date so that opening the shipping container will not disturb or otherwise alter any of the allograft tissue that is not being utilized.
(iii)The allograft tissue is intended for the express purpose of implantation into or application on a patient.
(iv)The allograft tissue is not intended for further distribution.
(v)The allograft tissue is registered with the FDA and designated to be maintained at ambient room temperature requiring no refrigeration.
(11)The storage or preparation for patient administration of tissue performed at a clinical trial site that is intended solely for investigational use by experts qualified by scientific training and experience to investigate the safety and effectiveness of drugs or devices if the investigation is conducted in accordance with the requirements of Section 505(i) of the federal Food, Drug, and Cosmetic Act (21 U.S.C. Sec. 355(i)) or Section 520(g) thereof (21 U.S.C. Sec. 360j(g)) and the regulations adopted pursuant to the federal act.
(12)The storage or distribution of pasteurized human milk that was obtained from a mothers milk bank, as defined in Section 14132.34 of the Welfare and Institutions Code, by a general acute care hospital.
SEC. 3.Section 10123.864 is added to the Insurance Code, to read:10123.864.A health insurance policy, except a specialized health insurance policy, that is issued, amended, delivered, or renewed on or after January 1, 2025, shall cover the same health benefits for human milk and human milk derivatives covered under the Medi-Cal program as of 1988.
SEC. 4.No reimbursement is required by this act pursuant to Section 6 of Article XIIIB of the California Constitution because the only costs that may be incurred by a local agency or school district will be incurred because this act creates a new crime or infraction, eliminates a crime or infraction, or changes the penalty for a crime or infraction, within the meaning of Section 17556 of the Government Code, or changes the definition of a crime within the meaning of Section 6 of Article XIIIB of the California Constitution.
SECTION 1.Section 1367.005 of the Health and Safety Code is amended to read:1367.005.(a)An individual or small group health care service plan contract issued, amended, or renewed on or after January 1, 2017, shall include, at a minimum, coverage for essential health benefits pursuant to the federal Patient Protection and Affordable Care Act (PPACA) and as outlined in this section. For purposes of this section, essential health benefits means all of the following:(1)Health benefits within the categories identified in Section 1302(b) of PPACA: ambulatory patient services, emergency services, hospitalization, maternity and newborn care, mental health and substance use disorder services, including behavioral health treatment, prescription drugs, rehabilitative and habilitative services and devices, laboratory services, preventive and wellness services and chronic disease management, and pediatric services, including oral and vision care.(2)(A)The health benefits covered by the Kaiser Foundation Health Plan Small Group HMO 30 plan (federal health product identification number 40513CA035) as this plan was offered during the first quarter of 2014, as follows, regardless of whether the benefits are specifically referenced in the evidence of coverage or plan contract for that plan:(i)Medically necessary basic health care services, as defined in subdivision (b) of Section 1345 and Section 1300.67 of Title 28 of the California Code of Regulations.(ii)The health benefits mandated to be covered by the plan pursuant to statutes enacted before December 31, 2011, as described in the following sections: Sections 1367.002, 1367.06, and 1367.35 (preventive services for children); Section 1367.25 (prescription drug coverage for contraceptives); Section 1367.45 (AIDS vaccine); Section 1367.46 (HIV testing); Section 1367.51 (diabetes); Section 1367.54 (alpha-fetoprotein testing); Section 1367.6 (breast cancer screening); Section 1367.61 (prosthetics for laryngectomy); Section 1367.62 (maternity hospital stay); Section 1367.63 (reconstructive surgery); Section 1367.635 (mastectomies); Section 1367.64 (prostate cancer); Section 1367.65 (mammography); Section 1367.66 (cervical cancer); Section 1367.665 (cancer screening tests); Section 1367.67 (osteoporosis); Section 1367.68 (surgical procedures for jaw bones); Section 1367.71 (anesthesia for dental); Section 1367.9 (conditions attributable to diethylstilbestrol); Section 1368.2 (hospice care); Section 1370.6 (cancer clinical trials); Section 1371.5 (emergency response ambulance or ambulance transport services); subdivision (b) of Section 1373 (sterilization operations or procedures); Section 1373.4 (inpatient hospital and ambulatory maternity); Section 1374.56 (phenylketonuria); Section 1374.17 (organ transplants for HIV); Section 1374.72 (mental health parity); and Section 1374.73 (autism/behavioral health treatment).(iii)Any other benefits mandated to be covered by the plan pursuant to statutes enacted before December 31, 2011, as described in those statutes.(iv)The health benefits covered by the plan that are not otherwise required to be covered under this chapter, to the extent required pursuant to Sections 1367.18, 1367.21, 1367.215, 1367.22, 1367.24, and 1367.25, and Section 1300.67.24 of Title 28 of the California Code of Regulations.(v)Any other health benefits covered by the plan that are not otherwise required to be covered under this chapter.(B)If there are any conflicts or omissions in the plan identified in subparagraph (A) as compared with the requirements for health benefits under this chapter that were enacted prior to December 31, 2011, the requirements of this chapter shall be controlling, except as otherwise specified in this section.(C)Notwithstanding subparagraph (B) or any other provision of this section, the home health services benefits covered under the plan identified in subparagraph (A) shall be deemed to not be in conflict with this chapter.(D)For purposes of this section, the Paul Wellstone and Pete Domenici Mental Health Parity and Addiction Equity Act of 2008 (Public Law 110-343) shall apply to a contract subject to this section. Coverage of mental health and substance use disorder services pursuant to this paragraph, along with any scope and duration limits imposed on the benefits, shall be in compliance with the Paul Wellstone and Pete Domenici Mental Health Parity and Addiction Equity Act of 2008 (Public Law 110-343), and all rules, regulations, or guidance issued pursuant to Section 2726 of the federal Public Health Service Act (42 U.S.C. Sec. 300gg-26).(3)With respect to habilitative services, in addition to any habilitative services and devices identified in paragraph (2), coverage shall also be provided as required by federal rules, regulations, and guidance issued pursuant to Section 1302(b) of PPACA. Habilitative services and devices shall be covered under the same terms and conditions applied to rehabilitative services and devices under the plan contract. Limits on habilitative and rehabilitative services and devices shall not be combined.(4)With respect to pediatric vision care, the same health benefits for pediatric vision care covered under the Federal Employees Dental and Vision Insurance Program vision plan with the largest national enrollment as of the first quarter of 2014. The pediatric vision care benefits covered pursuant to this paragraph shall be in addition to, and shall not replace, any vision services covered under the plan identified in paragraph (2).(5)With respect to pediatric oral care, the same health benefits for pediatric oral care covered under the dental benefit received by children under the Medi-Cal program as of 2014, including the provision of medically necessary orthodontic care provided pursuant to the federal Childrens Health Insurance Program Reauthorization Act of 2009. The pediatric oral care benefits covered pursuant to this paragraph shall be in addition to, and shall not replace, any dental or orthodontic services covered under the plan identified in paragraph (2).(6)With respect to maternity and newborn care, the same health benefits for human milk and human milk derivatives covered under the Medi-Cal program as of 1988. The benefits covered pursuant to this paragraph shall be in addition to, and shall not replace, any maternity or newborn services covered under the plan identified in paragraph (2).(b)Treatment limitations imposed on health benefits described in this section shall be no greater than the treatment limitations imposed by the corresponding plans identified in subdivision (a), subject to the requirements set forth in paragraph (2) of subdivision (a).(c)Except as provided in subdivision (d), this section does not permit a health care service plan to make substitutions for the benefits required to be covered under this section, regardless of whether those substitutions are actuarially equivalent.(d)To the extent permitted under Section 1302 of PPACA and any rules, regulations, or guidance issued pursuant to that section, and to the extent that substitution would not create an obligation for the state to defray costs for any individual, a plan may substitute its prescription drug formulary for the formulary provided under the plan identified in subdivision (a) if the coverage for prescription drugs complies with the sections referenced in clauses (ii) and (iv) of subparagraph (A) of paragraph (2) of subdivision (a) that apply to prescription drugs.(e)A health care service plan, or its agent, solicitor, or representative, shall not issue, deliver, renew, offer, market, represent, or sell any product, contract, or discount arrangement as compliant with the essential health benefits requirement in federal law, unless it meets all of the requirements of this section.(f)This section applies regardless of whether the plan contract is offered inside or outside the California Health Benefit Exchange created by Section 100500 of the Government Code.(g)This section does not exempt a plan or a plan contract from meeting other applicable requirements of law.(h)This section does not prohibit a plan contract from covering additional benefits, including, but not limited to, spiritual care services that are tax deductible under Section 213 of the Internal Revenue Code.(i)Subdivision (a) does not apply to any of the following:(1)A specialized health care service plan contract.(2)A Medicare supplement plan.(3)A plan contract that qualifies as a grandfathered health plan under Section 1251 of PPACA or any rules, regulations, or guidance issued pursuant to that section.(j)This section shall not be implemented in a manner that conflicts with a requirement of PPACA.(k)An essential health benefit is required to be provided under this section only to the extent that federal law does not require the state to defray the costs of the benefit.(l)This section does not obligate the state to incur costs for the coverage of benefits that are not essential health benefits as defined in this section.(m)A plan is not required to cover, under this section, changes to health benefits that are the result of statutes enacted on or after December 31, 2011.(n)(1)The department may adopt emergency regulations implementing this section. The department may, on a one-time basis, readopt any emergency regulation authorized by this section that is the same as, or substantially equivalent to, an emergency regulation previously adopted under this section.(2)The initial adoption of emergency regulations implementing this section and the readoption of emergency regulations authorized by this subdivision shall be deemed an emergency and necessary for the immediate preservation of the public peace, health, safety, or general welfare. The initial emergency regulations and the readoption of emergency regulations authorized by this section shall be submitted to the Office of Administrative Law for filing with the Secretary of State and each shall remain in effect for no more than 180 days, by which time final regulations may be adopted.(3)The initial adoption of emergency regulations implementing this section made during the 201516 Regular Session of the Legislature and the readoption of emergency regulations authorized by this subdivision shall be deemed an emergency and necessary for the immediate preservation of the public peace, health, safety, or general welfare. The initial emergency regulations and the readoption of emergency regulations authorized by this section shall be submitted to the Office of Administrative Law for filing with the Secretary of State and each shall remain in effect for no more than 180 days, by which time final regulations may be adopted.(4)The director shall consult with the Insurance Commissioner to ensure consistency and uniformity in the development of regulations under this subdivision.(5)This subdivision shall become inoperative on July 1, 2018.(o)For purposes of this section, the following definitions apply:(1)Habilitative services means health care services and devices that help a person keep, learn, or improve skills and functioning for daily living. Examples include therapy for a child who is not walking or talking at the expected age. These services may include physical and occupational therapy, speech-language pathology, and other services for people with disabilities in a variety of inpatient or outpatient settings, or both. Habilitative services shall be covered under the same terms and conditions applied to rehabilitative services under the plan contract.(2)(A)Health benefits, unless otherwise required to be defined pursuant to federal rules, regulations, or guidance issued pursuant to Section 1302(b) of PPACA, means health care items or services for the diagnosis, cure, mitigation, treatment, or prevention of illness, injury, disease, or a health condition, including a behavioral health condition.(B)Health benefits does not mean any cost-sharing requirements such as copayments, coinsurance, or deductibles.(3)PPACA means the federal Patient Protection and Affordable Care Act (Public Law 111-148), as amended by the federal Health Care and Education Reconciliation Act of 2010 (Public Law 111-152), and any rules, regulations, or guidance issued thereunder.(4)Small group health care service plan contract means a group health care service plan contract issued to a small employer, as defined in Section 1357.500.SEC. 2.Section 1635.1 of the Health and Safety Code is amended to read:1635.1.(a)Except as provided in subdivision (b), every tissue bank operating in California on or after July 1, 1992, shall have a current and valid tissue bank license issued or renewed by the department pursuant to Section 1639.2 or 1639.3.(b)This chapter does not apply to any of the following:(1)The collection, processing, storage, or distribution of human whole blood or its derivatives by blood banks licensed pursuant to Chapter 4 (commencing with Section 1600) or any person exempt from licensure under that chapter.(2)The collection, processing, storage, or distribution of tissue for autopsy, biopsy, training, education, or for other medical or scientific research or investigation, when transplantation of the tissue is not intended or reasonably foreseeable.(3)The collection of tissue by an individual physician and surgeon from their patient or the implantation of tissue by an individual physician and surgeon into their patient. This exemption shall not be interpreted to apply to any processing or storage of the tissue, except for the processing and storage of semen by an individual physician and surgeon when the semen was collected by that physician and surgeon from a semen donor or obtained by that physician and surgeon from a tissue bank licensed under this chapter.(4)The collection, processing, storage, or distribution of fetal tissue or tissue derived from a human embryo or fetus.(5)The collection, processing, storage, or distribution by an organ procurement organization (OPO), as defined in Section 486.302 of Title 42 of the Code of Federal Regulations, if the OPO, at the time of collection, processing, storage, and distribution of the tissue, has been designated by the Secretary of Health and Human Services as an OPO and meets the requirements of Sections 486.304 and 486.306 of Title 42 of the Code of Federal Regulations, as applicable.(6)The storage of prepackaged, freeze-dried bone by a general acute care hospital.(7)The storage of freeze-dried bone and dermis by any licensed dentist practicing in a lawful practice setting, if the freeze-dried bone and dermis have been obtained from a licensed tissue bank, are stored in strict accordance with a kits package insert and any other manufacturer instructions and guidelines, and are used for the express purpose of implantation into a patient.(8)The storage of a human cell, tissue, or cellular- or tissue-based product (HCT/P), as defined by the federal Food and Drug Administration (FDA), that is either a medical device approved pursuant to Section 510 or 515 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. Sec. 360 et seq.) or that is a biologic product approved under Section 351 of the federal Public Health Service Act (42 U.S.C. Sec. 262) by a licensed physician or podiatrist acting within the scope and authority of their license and practicing in a lawful practice setting. The medical device or biologic product must have been obtained from a California-licensed tissue bank, been stored in strict accordance with the devices or products package insert and any other manufacturer instructions, and used solely for the express purpose of direct implantation into or application on the practitioners own patient. In order to be eligible for the exemption in this paragraph, the entity or organization where the physician or podiatrist who is eligible for the exemption is practicing shall notify the department, in writing, that the practitioner is licensed and meets the requirements of this paragraph. The notification shall include all of the following:(A)A list of all practitioners to whom the notice applies.(B)Acknowledgment that each listed practitioner uses the medical device or biologic product in the scope and authority of their license and practice for the purposes of direct patient care as described in this paragraph.(C)A statement that each listed practitioner agrees to strictly abide by the directions for storage in the devices or products package insert and any other manufacturer instructions and guidelines.(D)Acknowledgment by each practitioner that the medical device or biologic product shall not be resold or distributed.(9)The collection, processing, storage, or distribution of any organ, as defined in paragraph (2) of subdivision (c) of Section 1635, within a single general acute care hospital, as defined in subdivision (a) of Section 1250, operating a Medicare-approved transplant program.(10)The storage of allograft tissue by a person if all of the following apply:(A)The person, as defined in Section 1635, is a hospital, or an outpatient setting regulated by the Medical Board of California pursuant to Chapter 1.3 (commencing with Section 1248), including an ambulatory surgical center.(B)The person maintains a log that includes the date on which the allograft tissue was received, the expiration date of the allograft tissue, the date on which each allograft tissue is used for clinical purposes, and the disposition of any allograft tissue samples that remain unused at the time the allograft tissue expires.(C)The allograft tissue meets all of the following:(i)The allograft tissue was obtained from a tissue bank licensed by the state.(ii)Each allograft tissue is individually boxed and labeled with a unique identification number and expiration date so that opening the shipping container will not disturb or otherwise alter any of the allograft tissue that is not being utilized.(iii)The allograft tissue is intended for the express purpose of implantation into or application on a patient.(iv)The allograft tissue is not intended for further distribution.(v)The allograft tissue is registered with the FDA and designated to be maintained at ambient room temperature requiring no refrigeration.(11)The storage or preparation for patient administration of tissue performed at a clinical trial site that is intended solely for investigational use by experts qualified by scientific training and experience to investigate the safety and effectiveness of drugs or devices if the investigation is conducted in accordance with the requirements of Section 505(i) of the federal Food, Drug, and Cosmetic Act (21 U.S.C. Sec. 355(i)) or Section 520(g) thereof (21 U.S.C. Sec. 360j(g)) and the regulations adopted pursuant to the federal act.(12)The storage or distribution of pasteurized human milk that was obtained from a mothers milk bank, as defined in Section 14132.34 of the Welfare and Institutions Code, by a general acute care hospital.SEC. 3.Section 10112.27 of the Insurance Code is amended to read:10112.27.(a)An individual or small group health insurance policy issued, amended, or renewed on or after January 1, 2017, shall include, at a minimum, coverage for essential health benefits pursuant to the federal Patient Protection and Affordable Care Act (PPACA) and as outlined in this section. This section shall exclusively govern the benefits a health insurer must cover as essential health benefits. For purposes of this section, essential health benefits means all of the following:(1)Health benefits within the categories identified in Section 1302(b) of PPACA: ambulatory patient services, emergency services, hospitalization, maternity and newborn care, mental health and substance use disorder services, including behavioral health treatment, prescription drugs, rehabilitative and habilitative services and devices, laboratory services, preventive and wellness services and chronic disease management, and pediatric services, including oral and vision care.(2)(A)The health benefits covered by the Kaiser Foundation Health Plan Small Group HMO 30 plan (federal health product identification number 40513CA035) as this plan was offered during the first quarter of 2014, as follows, regardless of whether the benefits are specifically referenced in the plan contract or evidence of coverage for that plan:(i)Medically necessary basic health care services, as defined in subdivision (b) of Section 1345 of the Health and Safety Code and Section 1300.67 of Title 28 of the California Code of Regulations.(ii)The health benefits mandated to be covered by the plan pursuant to statutes enacted before December 31, 2011, as described in the following sections of the Health and Safety Code: Sections 1367.002, 1367.06, and 1367.35 (preventive services for children); Section 1367.25 (prescription drug coverage for contraceptives); Section 1367.45 (AIDS vaccine); Section 1367.46 (HIV testing); Section 1367.51 (diabetes); Section 1367.54 (alpha-fetoprotein testing); Section 1367.6 (breast cancer screening); Section 1367.61 (prosthetics for laryngectomy); Section 1367.62 (maternity hospital stay); Section 1367.63 (reconstructive surgery); Section 1367.635 (mastectomies); Section 1367.64 (prostate cancer); Section 1367.65 (mammography); Section 1367.66 (cervical cancer); Section 1367.665 (cancer screening tests); Section 1367.67 (osteoporosis); Section 1367.68 (surgical procedures for jaw bones); Section 1367.71 (anesthesia for dental); Section 1367.9 (conditions attributable to diethylstilbestrol); Section 1368.2 (hospice care); Section 1370.6 (cancer clinical trials); Section 1371.5 (emergency response ambulance or ambulance transport services); subdivision (b) of Section 1373 (sterilization operations or procedures); Section 1373.4 (inpatient hospital and ambulatory maternity); Section 1374.56 (phenylketonuria); Section 1374.17 (organ transplants for HIV); Section 1374.72 (mental health parity); and Section 1374.73 (autism/behavioral health treatment).(iii)Any other benefits mandated to be covered by the plan pursuant to statutes enacted before December 31, 2011, as described in those statutes.(iv)The health benefits covered by the plan that are not otherwise required to be covered under Chapter 2.2 (commencing with Section 1340) of Division 2 of the Health and Safety Code, to the extent otherwise required pursuant to Sections 1367.18, 1367.21, 1367.215, 1367.22, 1367.24, and 1367.25 of the Health and Safety Code, and Section 1300.67.24 of Title 28 of the California Code of Regulations.(v)Any other health benefits covered by the plan that are not otherwise required to be covered under Chapter 2.2 (commencing with Section 1340) of Division 2 of the Health and Safety Code.(B)If there are any conflicts or omissions in the plan identified in subparagraph (A) as compared with the requirements for health benefits under Chapter 2.2 (commencing with Section 1340) of Division 2 of the Health and Safety Code that were enacted before December 31, 2011, the requirements of Chapter 2.2 (commencing with Section 1340) of Division 2 of the Health and Safety Code shall control, except as otherwise specified in this section.(C)Notwithstanding subparagraph (B) or any other provision of this section, the home health services benefits covered under the plan identified in subparagraph (A) shall not be in conflict with Chapter 2.2 (commencing with Section 1340) of Division 2 of the Health and Safety Code.(D)For purposes of this section, the Paul Wellstone and Pete Domenici Mental Health Parity and Addiction Equity Act of 2008 (Public Law 110-343) shall apply to a policy subject to this section. Coverage of mental health and substance use disorder services pursuant to this paragraph, along with any scope and duration limits imposed on the benefits, shall be in compliance with the Paul Wellstone and Pete Domenici Mental Health Parity and Addiction Equity Act of 2008 (Public Law 110-343), and all rules, regulations, and guidance issued pursuant to Section 2726 of the federal Public Health Service Act (42 U.S.C. Sec. 300gg-26).(3)With respect to habilitative services, in addition to any habilitative services and devices identified in paragraph (2), coverage shall also be provided as required by federal rules, regulations, or guidance issued pursuant to Section 1302(b) of PPACA. Habilitative services and devices shall be covered under the same terms and conditions applied to rehabilitative services and devices under the policy. Limits on habilitative and rehabilitative services and devices shall not be combined.(4)With respect to pediatric vision care, the same health benefits for pediatric vision care covered under the Federal Employees Dental and Vision Insurance Program vision plan with the largest national enrollment as of the first quarter of 2014. The pediatric vision care services covered pursuant to this paragraph shall be in addition to, and shall not replace, any vision services covered under the plan identified in paragraph (2).(5)With respect to pediatric oral care, the same health benefits for pediatric oral care covered under the dental benefit received by children under the Medi-Cal program as of 2014, including the provision of medically necessary orthodontic care provided pursuant to the federal Childrens Health Insurance Program Reauthorization Act of 2009. The pediatric oral care benefits covered pursuant to this paragraph shall be in addition to, and shall not replace, any dental or orthodontic services covered under the plan identified in paragraph (2).(6)With respect to maternity and newborn care, the same health benefits for human milk and human milk derivatives covered under the Medi-Cal program as of 1988. The benefits covered pursuant to this paragraph shall be in addition to, and shall not replace, any maternity or newborn services covered under the plan identified in paragraph (2).(b)Treatment limitations imposed on health benefits described in this section shall be no greater than the treatment limitations imposed by the corresponding plans identified in subdivision (a), subject to the requirements set forth in paragraph (2) of subdivision (a).(c)Except as provided in subdivision (d), this section does not permit a health insurer to make substitutions for the benefits required to be covered under this section, regardless of whether those substitutions are actuarially equivalent.(d)To the extent permitted under Section 1302 of PPACA and any rules, regulations, or guidance issued pursuant to that section, and to the extent that substitution would not create an obligation for the state to defray costs for any individual, an insurer may substitute its prescription drug formulary for the formulary provided under the plan identified in subdivision (a) if the coverage for prescription drugs complies with the sections referenced in clauses (ii) and (iv) of subparagraph (A) of paragraph (2) of subdivision (a) that apply to prescription drugs.(e)A health insurer, or its agent, producer, or representative, shall not issue, deliver, renew, offer, market, represent, or sell any product, policy, or discount arrangement as compliant with the essential health benefits requirement in federal law, unless it meets all of the requirements of this section. This subdivision shall be enforced in the same manner as Section 790.03, including through the means specified in Sections 790.035 and 790.05.(f)This section applies regardless of whether the policy is offered inside or outside the California Health Benefit Exchange created by Section 100500 of the Government Code.(g)This section does not exempt a health insurer or a health insurance policy from meeting other applicable requirements of law.(h)This section does not prohibit a policy from covering additional benefits, including, but not limited to, spiritual care services that are tax deductible under Section 213 of the Internal Revenue Code.(i)Subdivision (a) does not apply to any of the following:(1)A policy that provides excepted benefits as described in Sections 2722 and 2791 of the federal Public Health Service Act (42 U.S.C. Sec. 300gg-21; 42 U.S.C. Sec. 300gg-91).(2)A policy that qualifies as a grandfathered health plan under Section 1251 of PPACA or any binding rules, regulations, or guidance issued pursuant to that section.(j)This section shall not be implemented in a manner that conflicts with a requirement of PPACA.(k)An essential health benefit is required to be provided under this section only to the extent that federal law does not require the state to defray the costs of the benefit.(l)This section does not obligate the state to incur costs for the coverage of benefits that are not essential health benefits as defined in this section.(m)An insurer is not required to cover, under this section, changes to health benefits that are the result of statutes enacted on or after December 31, 2011.(n)(1)The commissioner may adopt emergency regulations implementing this section. The commissioner, on a one-time basis, may readopt any emergency regulation authorized by this section that is the same as, or substantially equivalent to, an emergency regulation previously adopted under this section.(2)The initial adoption of emergency regulations implementing this section and the readoption of emergency regulations authorized by this subdivision shall be deemed an emergency and necessary for the immediate preservation of the public peace, health, safety, or general welfare. The initial emergency regulations and the readoption of emergency regulations authorized by this section shall be submitted to the Office of Administrative Law for filing with the Secretary of State and each shall remain in effect for no more than 180 days, by which time final regulations may be adopted.(3)The initial adoption of emergency regulations implementing this section made during the 201516 Regular Session of the Legislature and the readoption of emergency regulations authorized by this subdivision shall be deemed an emergency and necessary for the immediate preservation of the public peace, health, safety, or general welfare. The initial emergency regulations and the readoption of emergency regulations authorized by this section shall be submitted to the Office of Administrative Law for filing with the Secretary of State and each shall remain in effect for no more than 180 days, by which time final regulations may be adopted.(4)The commissioner shall consult with the Director of the Department of Managed Health Care to ensure consistency and uniformity in the development of regulations under this subdivision.(5)This subdivision shall become inoperative on July 1, 2018.(o)This section does not impose on health insurance policies the cost sharing or network limitations of the plans identified in subdivision (a) except to the extent otherwise required to comply with this code, including this section, and as otherwise applicable to all health insurance policies offered to individuals and small groups.(p)For purposes of this section, the following definitions apply:(1)Habilitative services means health care services and devices that help a person keep, learn, or improve skills and functioning for daily living. Examples include therapy for a child who is not walking or talking at the expected age. These services may include physical and occupational therapy, speech-language pathology, and other services for people with disabilities in a variety of inpatient or outpatient settings, or both. Habilitative services shall be covered under the same terms and conditions applied to rehabilitative services under the policy.(2)(A)Health benefits, unless otherwise required to be defined pursuant to federal rules, regulations, or guidance issued pursuant to Section 1302(b) of PPACA, means health care items or services for the diagnosis, cure, mitigation, treatment, or prevention of illness, injury, disease, or a health condition, including a behavioral health condition.(B)Health benefits does not mean any cost-sharing requirements such as copayments, coinsurance, or deductibles.(3)PPACA means the federal Patient Protection and Affordable Care Act (Public Law 111-148), as amended by the federal Health Care and Education Reconciliation Act of 2010 (Public Law 111-152), and any rules, regulations, or guidance issued thereunder.(4)Small group health insurance policy means a group health insurance policy issued to a small employer, as defined in subdivision (q) of Section 10753.SEC. 4.No reimbursement is required by this act pursuant to Section 6 of Article XIIIB of the California Constitution because the only costs that may be incurred by a local agency or school district will be incurred because this act creates a new crime or infraction, eliminates a crime or infraction, or changes the penalty for a crime or infraction, within the meaning of Section 17556 of the Government Code, or changes the definition of a crime within the meaning of Section 6 of Article XIIIB of the California Constitution. REVISIONS: HeadingLine 2.(a)An individual or small group health care service plan contract issued, amended, or renewed on or after January 1, 2017, shall include, at a minimum, coverage for essential health benefits pursuant to the federal Patient Protection and Affordable Care Act (PPACA) and as outlined in this section. For purposes of this section, essential health benefits means all of the following:
(1)Health benefits within the categories identified in Section 1302(b) of PPACA: ambulatory patient services, emergency services, hospitalization, maternity and newborn care, mental health and substance use disorder services, including behavioral health treatment, prescription drugs, rehabilitative and habilitative services and devices, laboratory services, preventive and wellness services and chronic disease management, and pediatric services, including oral and vision care.
(2)(A)The health benefits covered by the Kaiser Foundation Health Plan Small Group HMO 30 plan (federal health product identification number 40513CA035) as this plan was offered during the first quarter of 2014, as follows, regardless of whether the benefits are specifically referenced in the evidence of coverage or plan contract for that plan:
(i)Medically necessary basic health care services, as defined in subdivision (b) of Section 1345 and Section 1300.67 of Title 28 of the California Code of Regulations.
(ii)The health benefits mandated to be covered by the plan pursuant to statutes enacted before December 31, 2011, as described in the following sections: Sections 1367.002, 1367.06, and 1367.35 (preventive services for children); Section 1367.25 (prescription drug coverage for contraceptives); Section 1367.45 (AIDS vaccine); Section 1367.46 (HIV testing); Section 1367.51 (diabetes); Section 1367.54 (alpha-fetoprotein testing); Section 1367.6 (breast cancer screening); Section 1367.61 (prosthetics for laryngectomy); Section 1367.62 (maternity hospital stay); Section 1367.63 (reconstructive surgery); Section 1367.635 (mastectomies); Section 1367.64 (prostate cancer); Section 1367.65 (mammography); Section 1367.66 (cervical cancer); Section 1367.665 (cancer screening tests); Section 1367.67 (osteoporosis); Section 1367.68 (surgical procedures for jaw bones); Section 1367.71 (anesthesia for dental); Section 1367.9 (conditions attributable to diethylstilbestrol); Section 1368.2 (hospice care); Section 1370.6 (cancer clinical trials); Section 1371.5 (emergency response ambulance or ambulance transport services); subdivision (b) of Section 1373 (sterilization operations or procedures); Section 1373.4 (inpatient hospital and ambulatory maternity); Section 1374.56 (phenylketonuria); Section 1374.17 (organ transplants for HIV); Section 1374.72 (mental health parity); and Section 1374.73 (autism/behavioral health treatment).
(iii)Any other benefits mandated to be covered by the plan pursuant to statutes enacted before December 31, 2011, as described in those statutes.
(iv)The health benefits covered by the plan that are not otherwise required to be covered under this chapter, to the extent required pursuant to Sections 1367.18, 1367.21, 1367.215, 1367.22, 1367.24, and 1367.25, and Section 1300.67.24 of Title 28 of the California Code of Regulations.
(v)Any other health benefits covered by the plan that are not otherwise required to be covered under this chapter.
(B)If there are any conflicts or omissions in the plan identified in subparagraph (A) as compared with the requirements for health benefits under this chapter that were enacted prior to December 31, 2011, the requirements of this chapter shall be controlling, except as otherwise specified in this section.
(C)Notwithstanding subparagraph (B) or any other provision of this section, the home health services benefits covered under the plan identified in subparagraph (A) shall be deemed to not be in conflict with this chapter.
(D)For purposes of this section, the Paul Wellstone and Pete Domenici Mental Health Parity and Addiction Equity Act of 2008 (Public Law 110-343) shall apply to a contract subject to this section. Coverage of mental health and substance use disorder services pursuant to this paragraph, along with any scope and duration limits imposed on the benefits, shall be in compliance with the Paul Wellstone and Pete Domenici Mental Health Parity and Addiction Equity Act of 2008 (Public Law 110-343), and all rules, regulations, or guidance issued pursuant to Section 2726 of the federal Public Health Service Act (42 U.S.C. Sec. 300gg-26).
(3)With respect to habilitative services, in addition to any habilitative services and devices identified in paragraph (2), coverage shall also be provided as required by federal rules, regulations, and guidance issued pursuant to Section 1302(b) of PPACA. Habilitative services and devices shall be covered under the same terms and conditions applied to rehabilitative services and devices under the plan contract. Limits on habilitative and rehabilitative services and devices shall not be combined.
(4)With respect to pediatric vision care, the same health benefits for pediatric vision care covered under the Federal Employees Dental and Vision Insurance Program vision plan with the largest national enrollment as of the first quarter of 2014. The pediatric vision care benefits covered pursuant to this paragraph shall be in addition to, and shall not replace, any vision services covered under the plan identified in paragraph (2).
(5)With respect to pediatric oral care, the same health benefits for pediatric oral care covered under the dental benefit received by children under the Medi-Cal program as of 2014, including the provision of medically necessary orthodontic care provided pursuant to the federal Childrens Health Insurance Program Reauthorization Act of 2009. The pediatric oral care benefits covered pursuant to this paragraph shall be in addition to, and shall not replace, any dental or orthodontic services covered under the plan identified in paragraph (2).
(6)With respect to maternity and newborn care, the same health benefits for human milk and human milk derivatives covered under the Medi-Cal program as of 1988. The benefits covered pursuant to this paragraph shall be in addition to, and shall not replace, any maternity or newborn services covered under the plan identified in paragraph (2).
(b)Treatment limitations imposed on health benefits described in this section shall be no greater than the treatment limitations imposed by the corresponding plans identified in subdivision (a), subject to the requirements set forth in paragraph (2) of subdivision (a).
(c)Except as provided in subdivision (d), this section does not permit a health care service plan to make substitutions for the benefits required to be covered under this section, regardless of whether those substitutions are actuarially equivalent.
(d)To the extent permitted under Section 1302 of PPACA and any rules, regulations, or guidance issued pursuant to that section, and to the extent that substitution would not create an obligation for the state to defray costs for any individual, a plan may substitute its prescription drug formulary for the formulary provided under the plan identified in subdivision (a) if the coverage for prescription drugs complies with the sections referenced in clauses (ii) and (iv) of subparagraph (A) of paragraph (2) of subdivision (a) that apply to prescription drugs.
(e)A health care service plan, or its agent, solicitor, or representative, shall not issue, deliver, renew, offer, market, represent, or sell any product, contract, or discount arrangement as compliant with the essential health benefits requirement in federal law, unless it meets all of the requirements of this section.
(f)This section applies regardless of whether the plan contract is offered inside or outside the California Health Benefit Exchange created by Section 100500 of the Government Code.
(g)This section does not exempt a plan or a plan contract from meeting other applicable requirements of law.
(h)This section does not prohibit a plan contract from covering additional benefits, including, but not limited to, spiritual care services that are tax deductible under Section 213 of the Internal Revenue Code.
(i)Subdivision (a) does not apply to any of the following:
(1)A specialized health care service plan contract.
(2)A Medicare supplement plan.
(3)A plan contract that qualifies as a grandfathered health plan under Section 1251 of PPACA or any rules, regulations, or guidance issued pursuant to that section.
(j)This section shall not be implemented in a manner that conflicts with a requirement of PPACA.
(k)An essential health benefit is required to be provided under this section only to the extent that federal law does not require the state to defray the costs of the benefit.
(l)This section does not obligate the state to incur costs for the coverage of benefits that are not essential health benefits as defined in this section.
(m)A plan is not required to cover, under this section, changes to health benefits that are the result of statutes enacted on or after December 31, 2011.
(n)(1)The department may adopt emergency regulations implementing this section. The department may, on a one-time basis, readopt any emergency regulation authorized by this section that is the same as, or substantially equivalent to, an emergency regulation previously adopted under this section.
(2)The initial adoption of emergency regulations implementing this section and the readoption of emergency regulations authorized by this subdivision shall be deemed an emergency and necessary for the immediate preservation of the public peace, health, safety, or general welfare. The initial emergency regulations and the readoption of emergency regulations authorized by this section shall be submitted to the Office of Administrative Law for filing with the Secretary of State and each shall remain in effect for no more than 180 days, by which time final regulations may be adopted.
(3)The initial adoption of emergency regulations implementing this section made during the 201516 Regular Session of the Legislature and the readoption of emergency regulations authorized by this subdivision shall be deemed an emergency and necessary for the immediate preservation of the public peace, health, safety, or general welfare. The initial emergency regulations and the readoption of emergency regulations authorized by this section shall be submitted to the Office of Administrative Law for filing with the Secretary of State and each shall remain in effect for no more than 180 days, by which time final regulations may be adopted.
(4)The director shall consult with the Insurance Commissioner to ensure consistency and uniformity in the development of regulations under this subdivision.
(5)This subdivision shall become inoperative on July 1, 2018.
(o)For purposes of this section, the following definitions apply:
(1)Habilitative services means health care services and devices that help a person keep, learn, or improve skills and functioning for daily living. Examples include therapy for a child who is not walking or talking at the expected age. These services may include physical and occupational therapy, speech-language pathology, and other services for people with disabilities in a variety of inpatient or outpatient settings, or both. Habilitative services shall be covered under the same terms and conditions applied to rehabilitative services under the plan contract.
(2)(A)Health benefits, unless otherwise required to be defined pursuant to federal rules, regulations, or guidance issued pursuant to Section 1302(b) of PPACA, means health care items or services for the diagnosis, cure, mitigation, treatment, or prevention of illness, injury, disease, or a health condition, including a behavioral health condition.
(B)Health benefits does not mean any cost-sharing requirements such as copayments, coinsurance, or deductibles.
(3)PPACA means the federal Patient Protection and Affordable Care Act (Public Law 111-148), as amended by the federal Health Care and Education Reconciliation Act of 2010 (Public Law 111-152), and any rules, regulations, or guidance issued thereunder.
(4)Small group health care service plan contract means a group health care service plan contract issued to a small employer, as defined in Section 1357.500.
SEC. 2.Section 1635.1 of the Health and Safety Code is amended to read:1635.1.(a)Except as provided in subdivision (b), every tissue bank operating in California on or after July 1, 1992, shall have a current and valid tissue bank license issued or renewed by the department pursuant to Section 1639.2 or 1639.3.
(b)This chapter does not apply to any of the following:
(1)The collection, processing, storage, or distribution of human whole blood or its derivatives by blood banks licensed pursuant to Chapter 4 (commencing with Section 1600) or any person exempt from licensure under that chapter.
(2)The collection, processing, storage, or distribution of tissue for autopsy, biopsy, training, education, or for other medical or scientific research or investigation, when transplantation of the tissue is not intended or reasonably foreseeable.
(3)The collection of tissue by an individual physician and surgeon from their patient or the implantation of tissue by an individual physician and surgeon into their patient. This exemption shall not be interpreted to apply to any processing or storage of the tissue, except for the processing and storage of semen by an individual physician and surgeon when the semen was collected by that physician and surgeon from a semen donor or obtained by that physician and surgeon from a tissue bank licensed under this chapter.
(4)The collection, processing, storage, or distribution of fetal tissue or tissue derived from a human embryo or fetus.
(5)The collection, processing, storage, or distribution by an organ procurement organization (OPO), as defined in Section 486.302 of Title 42 of the Code of Federal Regulations, if the OPO, at the time of collection, processing, storage, and distribution of the tissue, has been designated by the Secretary of Health and Human Services as an OPO and meets the requirements of Sections 486.304 and 486.306 of Title 42 of the Code of Federal Regulations, as applicable.
(6)The storage of prepackaged, freeze-dried bone by a general acute care hospital.
(7)The storage of freeze-dried bone and dermis by any licensed dentist practicing in a lawful practice setting, if the freeze-dried bone and dermis have been obtained from a licensed tissue bank, are stored in strict accordance with a kits package insert and any other manufacturer instructions and guidelines, and are used for the express purpose of implantation into a patient.
(8)The storage of a human cell, tissue, or cellular- or tissue-based product (HCT/P), as defined by the federal Food and Drug Administration (FDA), that is either a medical device approved pursuant to Section 510 or 515 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. Sec. 360 et seq.) or that is a biologic product approved under Section 351 of the federal Public Health Service Act (42 U.S.C. Sec. 262) by a licensed physician or podiatrist acting within the scope and authority of their license and practicing in a lawful practice setting. The medical device or biologic product must have been obtained from a California-licensed tissue bank, been stored in strict accordance with the devices or products package insert and any other manufacturer instructions, and used solely for the express purpose of direct implantation into or application on the practitioners own patient. In order to be eligible for the exemption in this paragraph, the entity or organization where the physician or podiatrist who is eligible for the exemption is practicing shall notify the department, in writing, that the practitioner is licensed and meets the requirements of this paragraph. The notification shall include all of the following:
(A)A list of all practitioners to whom the notice applies.
(B)Acknowledgment that each listed practitioner uses the medical device or biologic product in the scope and authority of their license and practice for the purposes of direct patient care as described in this paragraph.
(C)A statement that each listed practitioner agrees to strictly abide by the directions for storage in the devices or products package insert and any other manufacturer instructions and guidelines.
(D)Acknowledgment by each practitioner that the medical device or biologic product shall not be resold or distributed.
(9)The collection, processing, storage, or distribution of any organ, as defined in paragraph (2) of subdivision (c) of Section 1635, within a single general acute care hospital, as defined in subdivision (a) of Section 1250, operating a Medicare-approved transplant program.
(10)The storage of allograft tissue by a person if all of the following apply:
(A)The person, as defined in Section 1635, is a hospital, or an outpatient setting regulated by the Medical Board of California pursuant to Chapter 1.3 (commencing with Section 1248), including an ambulatory surgical center.
(B)The person maintains a log that includes the date on which the allograft tissue was received, the expiration date of the allograft tissue, the date on which each allograft tissue is used for clinical purposes, and the disposition of any allograft tissue samples that remain unused at the time the allograft tissue expires.
(C)The allograft tissue meets all of the following:
(i)The allograft tissue was obtained from a tissue bank licensed by the state.
(ii)Each allograft tissue is individually boxed and labeled with a unique identification number and expiration date so that opening the shipping container will not disturb or otherwise alter any of the allograft tissue that is not being utilized.
(iii)The allograft tissue is intended for the express purpose of implantation into or application on a patient.
(iv)The allograft tissue is not intended for further distribution.
(v)The allograft tissue is registered with the FDA and designated to be maintained at ambient room temperature requiring no refrigeration.
(11)The storage or preparation for patient administration of tissue performed at a clinical trial site that is intended solely for investigational use by experts qualified by scientific training and experience to investigate the safety and effectiveness of drugs or devices if the investigation is conducted in accordance with the requirements of Section 505(i) of the federal Food, Drug, and Cosmetic Act (21 U.S.C. Sec. 355(i)) or Section 520(g) thereof (21 U.S.C. Sec. 360j(g)) and the regulations adopted pursuant to the federal act.
(12)The storage or distribution of pasteurized human milk that was obtained from a mothers milk bank, as defined in Section 14132.34 of the Welfare and Institutions Code, by a general acute care hospital.
SEC. 3.Section 10112.27 of the Insurance Code is amended to read:10112.27.(a)An individual or small group health insurance policy issued, amended, or renewed on or after January 1, 2017, shall include, at a minimum, coverage for essential health benefits pursuant to the federal Patient Protection and Affordable Care Act (PPACA) and as outlined in this section. This section shall exclusively govern the benefits a health insurer must cover as essential health benefits. For purposes of this section, essential health benefits means all of the following:
(1)Health benefits within the categories identified in Section 1302(b) of PPACA: ambulatory patient services, emergency services, hospitalization, maternity and newborn care, mental health and substance use disorder services, including behavioral health treatment, prescription drugs, rehabilitative and habilitative services and devices, laboratory services, preventive and wellness services and chronic disease management, and pediatric services, including oral and vision care.
(2)(A)The health benefits covered by the Kaiser Foundation Health Plan Small Group HMO 30 plan (federal health product identification number 40513CA035) as this plan was offered during the first quarter of 2014, as follows, regardless of whether the benefits are specifically referenced in the plan contract or evidence of coverage for that plan:
(i)Medically necessary basic health care services, as defined in subdivision (b) of Section 1345 of the Health and Safety Code and Section 1300.67 of Title 28 of the California Code of Regulations.
(ii)The health benefits mandated to be covered by the plan pursuant to statutes enacted before December 31, 2011, as described in the following sections of the Health and Safety Code: Sections 1367.002, 1367.06, and 1367.35 (preventive services for children); Section 1367.25 (prescription drug coverage for contraceptives); Section 1367.45 (AIDS vaccine); Section 1367.46 (HIV testing); Section 1367.51 (diabetes); Section 1367.54 (alpha-fetoprotein testing); Section 1367.6 (breast cancer screening); Section 1367.61 (prosthetics for laryngectomy); Section 1367.62 (maternity hospital stay); Section 1367.63 (reconstructive surgery); Section 1367.635 (mastectomies); Section 1367.64 (prostate cancer); Section 1367.65 (mammography); Section 1367.66 (cervical cancer); Section 1367.665 (cancer screening tests); Section 1367.67 (osteoporosis); Section 1367.68 (surgical procedures for jaw bones); Section 1367.71 (anesthesia for dental); Section 1367.9 (conditions attributable to diethylstilbestrol); Section 1368.2 (hospice care); Section 1370.6 (cancer clinical trials); Section 1371.5 (emergency response ambulance or ambulance transport services); subdivision (b) of Section 1373 (sterilization operations or procedures); Section 1373.4 (inpatient hospital and ambulatory maternity); Section 1374.56 (phenylketonuria); Section 1374.17 (organ transplants for HIV); Section 1374.72 (mental health parity); and Section 1374.73 (autism/behavioral health treatment).
(iii)Any other benefits mandated to be covered by the plan pursuant to statutes enacted before December 31, 2011, as described in those statutes.
(iv)The health benefits covered by the plan that are not otherwise required to be covered under Chapter 2.2 (commencing with Section 1340) of Division 2 of the Health and Safety Code, to the extent otherwise required pursuant to Sections 1367.18, 1367.21, 1367.215, 1367.22, 1367.24, and 1367.25 of the Health and Safety Code, and Section 1300.67.24 of Title 28 of the California Code of Regulations.
(v)Any other health benefits covered by the plan that are not otherwise required to be covered under Chapter 2.2 (commencing with Section 1340) of Division 2 of the Health and Safety Code.
(B)If there are any conflicts or omissions in the plan identified in subparagraph (A) as compared with the requirements for health benefits under Chapter 2.2 (commencing with Section 1340) of Division 2 of the Health and Safety Code that were enacted before December 31, 2011, the requirements of Chapter 2.2 (commencing with Section 1340) of Division 2 of the Health and Safety Code shall control, except as otherwise specified in this section.
(C)Notwithstanding subparagraph (B) or any other provision of this section, the home health services benefits covered under the plan identified in subparagraph (A) shall not be in conflict with Chapter 2.2 (commencing with Section 1340) of Division 2 of the Health and Safety Code.
(D)For purposes of this section, the Paul Wellstone and Pete Domenici Mental Health Parity and Addiction Equity Act of 2008 (Public Law 110-343) shall apply to a policy subject to this section. Coverage of mental health and substance use disorder services pursuant to this paragraph, along with any scope and duration limits imposed on the benefits, shall be in compliance with the Paul Wellstone and Pete Domenici Mental Health Parity and Addiction Equity Act of 2008 (Public Law 110-343), and all rules, regulations, and guidance issued pursuant to Section 2726 of the federal Public Health Service Act (42 U.S.C. Sec. 300gg-26).
(3)With respect to habilitative services, in addition to any habilitative services and devices identified in paragraph (2), coverage shall also be provided as required by federal rules, regulations, or guidance issued pursuant to Section 1302(b) of PPACA. Habilitative services and devices shall be covered under the same terms and conditions applied to rehabilitative services and devices under the policy. Limits on habilitative and rehabilitative services and devices shall not be combined.
(4)With respect to pediatric vision care, the same health benefits for pediatric vision care covered under the Federal Employees Dental and Vision Insurance Program vision plan with the largest national enrollment as of the first quarter of 2014. The pediatric vision care services covered pursuant to this paragraph shall be in addition to, and shall not replace, any vision services covered under the plan identified in paragraph (2).
(5)With respect to pediatric oral care, the same health benefits for pediatric oral care covered under the dental benefit received by children under the Medi-Cal program as of 2014, including the provision of medically necessary orthodontic care provided pursuant to the federal Childrens Health Insurance Program Reauthorization Act of 2009. The pediatric oral care benefits covered pursuant to this paragraph shall be in addition to, and shall not replace, any dental or orthodontic services covered under the plan identified in paragraph (2).
(6)With respect to maternity and newborn care, the same health benefits for human milk and human milk derivatives covered under the Medi-Cal program as of 1988. The benefits covered pursuant to this paragraph shall be in addition to, and shall not replace, any maternity or newborn services covered under the plan identified in paragraph (2).
(b)Treatment limitations imposed on health benefits described in this section shall be no greater than the treatment limitations imposed by the corresponding plans identified in subdivision (a), subject to the requirements set forth in paragraph (2) of subdivision (a).
(c)Except as provided in subdivision (d), this section does not permit a health insurer to make substitutions for the benefits required to be covered under this section, regardless of whether those substitutions are actuarially equivalent.
(d)To the extent permitted under Section 1302 of PPACA and any rules, regulations, or guidance issued pursuant to that section, and to the extent that substitution would not create an obligation for the state to defray costs for any individual, an insurer may substitute its prescription drug formulary for the formulary provided under the plan identified in subdivision (a) if the coverage for prescription drugs complies with the sections referenced in clauses (ii) and (iv) of subparagraph (A) of paragraph (2) of subdivision (a) that apply to prescription drugs.
(e)A health insurer, or its agent, producer, or representative, shall not issue, deliver, renew, offer, market, represent, or sell any product, policy, or discount arrangement as compliant with the essential health benefits requirement in federal law, unless it meets all of the requirements of this section. This subdivision shall be enforced in the same manner as Section 790.03, including through the means specified in Sections 790.035 and 790.05.
(f)This section applies regardless of whether the policy is offered inside or outside the California Health Benefit Exchange created by Section 100500 of the Government Code.
(g)This section does not exempt a health insurer or a health insurance policy from meeting other applicable requirements of law.
(h)This section does not prohibit a policy from covering additional benefits, including, but not limited to, spiritual care services that are tax deductible under Section 213 of the Internal Revenue Code.
(i)Subdivision (a) does not apply to any of the following:
(1)A policy that provides excepted benefits as described in Sections 2722 and 2791 of the federal Public Health Service Act (42 U.S.C. Sec. 300gg-21; 42 U.S.C. Sec. 300gg-91).
(2)A policy that qualifies as a grandfathered health plan under Section 1251 of PPACA or any binding rules, regulations, or guidance issued pursuant to that section.
(j)This section shall not be implemented in a manner that conflicts with a requirement of PPACA.
(k)An essential health benefit is required to be provided under this section only to the extent that federal law does not require the state to defray the costs of the benefit.
(l)This section does not obligate the state to incur costs for the coverage of benefits that are not essential health benefits as defined in this section.
(m)An insurer is not required to cover, under this section, changes to health benefits that are the result of statutes enacted on or after December 31, 2011.
(n)(1)The commissioner may adopt emergency regulations implementing this section. The commissioner, on a one-time basis, may readopt any emergency regulation authorized by this section that is the same as, or substantially equivalent to, an emergency regulation previously adopted under this section.
(2)The initial adoption of emergency regulations implementing this section and the readoption of emergency regulations authorized by this subdivision shall be deemed an emergency and necessary for the immediate preservation of the public peace, health, safety, or general welfare. The initial emergency regulations and the readoption of emergency regulations authorized by this section shall be submitted to the Office of Administrative Law for filing with the Secretary of State and each shall remain in effect for no more than 180 days, by which time final regulations may be adopted.
(3)The initial adoption of emergency regulations implementing this section made during the 201516 Regular Session of the Legislature and the readoption of emergency regulations authorized by this subdivision shall be deemed an emergency and necessary for the immediate preservation of the public peace, health, safety, or general welfare. The initial emergency regulations and the readoption of emergency regulations authorized by this section shall be submitted to the Office of Administrative Law for filing with the Secretary of State and each shall remain in effect for no more than 180 days, by which time final regulations may be adopted.
(4)The commissioner shall consult with the Director of the Department of Managed Health Care to ensure consistency and uniformity in the development of regulations under this subdivision.
(5)This subdivision shall become inoperative on July 1, 2018.
(o)This section does not impose on health insurance policies the cost sharing or network limitations of the plans identified in subdivision (a) except to the extent otherwise required to comply with this code, including this section, and as otherwise applicable to all health insurance policies offered to individuals and small groups.
(p)For purposes of this section, the following definitions apply:
(1)Habilitative services means health care services and devices that help a person keep, learn, or improve skills and functioning for daily living. Examples include therapy for a child who is not walking or talking at the expected age. These services may include physical and occupational therapy, speech-language pathology, and other services for people with disabilities in a variety of inpatient or outpatient settings, or both. Habilitative services shall be covered under the same terms and conditions applied to rehabilitative services under the policy.
(2)(A)Health benefits, unless otherwise required to be defined pursuant to federal rules, regulations, or guidance issued pursuant to Section 1302(b) of PPACA, means health care items or services for the diagnosis, cure, mitigation, treatment, or prevention of illness, injury, disease, or a health condition, including a behavioral health condition.
(B)Health benefits does not mean any cost-sharing requirements such as copayments, coinsurance, or deductibles.
(3)PPACA means the federal Patient Protection and Affordable Care Act (Public Law 111-148), as amended by the federal Health Care and Education Reconciliation Act of 2010 (Public Law 111-152), and any rules, regulations, or guidance issued thereunder.
(4)Small group health insurance policy means a group health insurance policy issued to a small employer, as defined in subdivision (q) of Section 10753.
SEC. 4.No reimbursement is required by this act pursuant to Section 6 of Article XIIIB of the California Constitution because the only costs that may be incurred by a local agency or school district will be incurred because this act creates a new crime or infraction, eliminates a crime or infraction, or changes the penalty for a crime or infraction, within the meaning of Section 17556 of the Government Code, or changes the definition of a crime within the meaning of Section 6 of Article XIIIB of the California Constitution.
|
Date
|
Status
|
|---|---|
| Sep 29, 2024 | Chaptered by Secretary of State - Chapter 975, Statutes of 2024. |
| Sep 29, 2024 | Approved by the Governor. |
| Sep 6, 2024 | Enrolled and presented to the Governor at 4 p.m. |
| Aug 28, 2024 | Senate amendments concurred in. To Engrossing and Enrolling. (Ayes 77. Noes 0.). |
| Aug 28, 2024 | Assembly Rule 77 suspended. |
| Aug 28, 2024 | In Assembly. Concurrence in Senate amendments pending. May be considered on or after August 30 pursuant to Assembly Rule 77. |
| Aug 27, 2024 | Read third time. Passed. Ordered to the Assembly. (Ayes 36. Noes 0.). |
| Aug 21, 2024 | Read second time. Ordered to third reading. |
| Aug 20, 2024 | Read third time and amended. Ordered to second reading. |
| Aug 19, 2024 | Read second time. Ordered to third reading. |
| Aug 15, 2024 | From committee: Do pass. (Ayes 4. Noes 1.) (August 15). |
| Aug 5, 2024 | In committee: Referred to APPR suspense file. |
| Jun 26, 2024 | From committee: Do pass and re-refer to Com. on APPR. (Ayes 11. Noes 0.) (June 26). Re-referred to Com. on APPR. |
| Jun 17, 2024 | From committee chair, with author's amendments: Amend, and re-refer to committee. Read second time, amended, and re-referred to Com. on HEALTH. |
| Jun 5, 2024 | Referred to Com. on HEALTH. |
| May 23, 2024 | In Senate. Read first time. To Com. on RLS. for assignment. |
| May 22, 2024 | Read third time. Passed. Ordered to the Senate. (Ayes 71. Noes 0. Page 5525.) |
| May 20, 2024 | Read second time. Ordered to third reading. |
| May 16, 2024 | From committee: Do pass. (Ayes 15. Noes 0.) (May 16). |
| May 8, 2024 | In committee: Set, first hearing. Referred to APPR. suspense file. |
| Apr 24, 2024 | From committee: Do pass and re-refer to Com. on APPR. (Ayes 16. Noes 0.) (April 23). Re-referred to Com. on APPR. |
| Apr 24, 2024 | Coauthors revised. |
| Mar 12, 2024 | Re-referred to Com. on HEALTH. |
| Mar 11, 2024 | From committee chair, with author's amendments: Amend, and re-refer to Com. on HEALTH. Read second time and amended. |
| Mar 11, 2024 | Referred to Com. on HEALTH. |
| Feb 17, 2024 | From printer. May be heard in committee March 18. |
| Feb 16, 2024 | Read first time. To print. |
|
Date
|
Description
|
Location
|
Votes
|
|
|---|---|---|---|---|
| Aug 28, 2024 | AB 3059 Weber Concurrence in Senate Amendments | Assembly Floor |
Passed |
|
| Aug 27, 2024 | Assembly 3rd Reading AB3059 Weber et al. By Limón | Senate Floor |
Passed |
|
| Aug 15, 2024 | Do pass | Senate Standing Committee on Appropriations |
Passed |
|
| Aug 5, 2024 | Placed on suspense file | Senate Standing Committee on Appropriations |
Passed |
|
| Jun 26, 2024 | Do pass, but first be re-referred to the Committee on [Appropriations] | Senate Standing Committee on Health |
Passed |
|
| May 22, 2024 | AB 3059 Weber Assembly Third Reading | Assembly Floor |
Passed |
|
| May 16, 2024 | Do pass. | Assembly Standing Committee on Appropriations |
Passed |
|
| Apr 23, 2024 | Do pass and be re-referred to the Committee on [Appropriations] | Assembly Standing Committee on Health |
Passed |
This list shows positions taken on this bill by organizations on the date displayed, which is linked to the original source.
Positions by individuals are not included.
|
Organization
|
Position
|
Date
|
|---|---|---|
| American Academy Of Pediatrics, California | ** Support | |
| American College Of Obstetricians And Gynecologists District Ix | ** Support | |
| AmericaS Health Insurance Plans | ** Against | |
| Association Of California Life And Health Insurance Companies | ** Against | |
| BreastfeedLA | ** Support | |
| California Association Of Health Plans | ** Against | |
| California Association Of Public Hospitals Health Systems | ** Support | |
| California Association of Women's Health, Obstetric and Neonatal Nurses | ** Support | |
| California Hospital Association | ** Support | |
| California Life Sciences | ** Support | |
| California Medical Association | ** Support | |
| California Wic Association | ** Support | |
| Children'S Specialty Care Coalition | ** Support | |
| County of Santa Clara | ** Support | |
| Human Milk Banking Association of North America | ** Support | |
| Human Milk Connection | ** Support | |
| Mothers' Milk Bank | ** Support | |
| PROLACTA BIOSCIENCE | ** Support | |
| Sharp Healthcare | ** Support | |
| UC San Diego's Human Milk Institute | ** Support | |
| University of California | ** Support |
CONCURRENCE IN SENATE AMENDMENTS
CSA1 Bill Id:AB 3059
Author:(Weber)
As Amended Ver:August 20, 2024
Majority vote
SUMMARY
Requires coverage of medically necessary pasteurized donor human milk (DHM) under existing basic health care services, as specified. Exempts from tissue bank licensure by the Department of Public Health (DPH), the storage or distribution of human milk that was obtained from a tissue bank, by a general acute care hospital. Requires hospitals that collect, process, store, or distribute human milk in any other circumstance to obtain a tissue bank license.
Senate Amendments
Delete reference to human milk and human milk derivatives covered under the Medi-Cal program to instead clarify that coverage of basic health care services includes medically necessary pasteurized DHM obtained from a tissue bank licensed by DPH.
COMMENTS
The American Academy of Pediatrics (AAP) recommends exclusive feeding with human milk for the first six months of life, with the continuation of feeding for 1 year or longer as mutually desired by mother and infant. In addition, the AAP recommends that when mother's own milk is not available that DHM be provided to all preterm and low-birthweight. DHM is provided through human milk banks that collect DHM, screen it for disease, pasteurize it, and freeze it for distribution to hospitals for use in the neonatal intensive care unit (NICU) setting. Necrotizing Enterocolitis is a severe disease of the intestinal tract and is one of the main causes of morbidity and mortality among very low–birthweight (VLBW) infants.
- Tissue bank requirements. All California hospitals that collect, process, store, or distribute human milk collected from a mother exclusively for her own child must follow Human Milk Banking Association of North America standards. DPH requires all hospitals that store DHM to hold a tissue bank license. California law defines a tissue bank as a place, establishment, or institution that collects, processes, stores, or distributes tissue for transplantation into human beings. California requires tissue banks operating in California on or after July 1, 1992, to have a current and valid tissue bank license from DPH. The law includes exemptions for certain procedures; however, the storage or distribution of pasteurized human milk is not among them. California milk banks that meet the state's statutory definition of a mothers' milk bank that applied for a tissue bank license before January 1, 1995, are exempt from the application and annual renewal fee for a tissue bank license. There are two milk banks that meet the state's definition of a mothers' milk bank: Mothers' Milk Bank in San Jose was founded in 1974, and the University of California (UC) Health Milk Bank was founded in 2020. The UC Health Milk Bank is required to hold a valid tissue bank license to operate, whereas the Mothers' Milk Bank in San Jose is exempt.
According to the author, milk banks that collect and process unpasteurized milk should have a tissue bank license, while hospitals that are only storing and distributing the pasteurized donor milk product should not. California currently exempts hospitals from obtaining a tissue bank license for the purpose of collecting, processing, storing or distributing human milk collected from a mother exclusively for her own child. Hospitals follow the same safety protocols for storing and distributing pasteurized DHM as a mother's own milk. This bill exempts the storage or distribution of DHM from tissue bank licensure.
- California Health Benefits Review Program (CHBRP) analysis. CHBRP's analysis of this bill includes the following:
- Assumptions. This bill would affect coverage of two health services: DHM and human milk-derived fortifiers (HMF). At baseline, CHBRP estimates that 39.13% of enrollees with health insurance subject to this bill have coverage for DHM and HMF. Postmandate, CHBRP estimates that 100% of enrollees with health insurance subject to this bill would have coverage for these benefits.
- Impact on expenditures. In 2025, this bill would result in, approximately, an additional $9,668,000 (0.00006%) in total net annual expenditures. This is inclusive of an approximate $8.6 million shift in expenses for DHM and HMF from providers (hospitals) to health insurance subject to this bill, and cost offsets due to an estimated increase in prevented cases of NEC and Bronchopulmanary Dysplasia (BPD). CHBRP estimates this bill would result in an additional 35 enrollees (1%) utilizing DHM and an additional 11 enrollees utilizing HMF. In the first year postmandate, CHBRP estimates this bill would lead to universal access to DHM in California through the removal of requirements for hospitals to be licensed as a tissue bank in order to provide DHM to patients, and that there would be a reduction in the average number of NEC and BPD cases of 0.62 and 1.75 cases per year, respectively, as well as a corresponding reduction in length of hospital stay (18 days for medically treated NEC; 50 days for surgically-treated NEC; 26 days for BPD).
- Premiums for enrollees in individual plans purchased through Covered California would increase by a total of $1,307,000 in annual expenditures, a 0.0083% increase.
- Medi-Cal. At baseline, Medi-Cal beneficiaries in the Department of Managed Health Care (DMHC)-regulated plans have 100% coverage for human milk and human milk derivatives. In DMHC-regulated Medi-Cal plans, total premiums would decrease by $36,000 (0.0001%).
- CalPERS. For enrollees associated with the California Public Enrollees' Retirement System (CalPERS) in DMHC-regulated plans, premiums would increase by 0.0079% ($0.0621 per member per month, or $553,000 total increase in expenditures).
- Number of Uninsured in California. CHBRP estimates this bill would have no measurable impact on the number of uninsured persons.
- Essential Health Benefits (EHBs). In California, nongrandfathered individual and small-group health insurance is generally required to cover EHBs. According to CHBRP, this bill would not appear to exceed the definition of EHBs in California.
- Public health. In the first year postmandate, CHBRP estimates that there would be a reduction in the average number of NEC and BPD cases per year, respectively, as well as a corresponding reduction in length of hospital stay (18 days for medically-treated NEC; 50 days for surgically-treated NEC; 26 days for BPD). This estimate is supported by clear and convincing evidence that DHM is medically effective in preventing NEC and BPD in preterm infants and an estimated increase in utilization (1%) of DHM. CHBRP estimates this bill would lead to universal access to DHM in California through the removal of requirements for hospitals to be licensed as a tissue bank in order to provide DHM to their patients and through reimbursement of these treatments. This could reduce disparities in receipt of DHM between infants with an inpatient stay at a smaller hospital.
- Assumptions. This bill would affect coverage of two health services: DHM and human milk-derived fortifiers (HMF). At baseline, CHBRP estimates that 39.13% of enrollees with health insurance subject to this bill have coverage for DHM and HMF. Postmandate, CHBRP estimates that 100% of enrollees with health insurance subject to this bill would have coverage for these benefits.
According to the Author
Addressing disparities in health care means looking at access to life-saving nutrition. The mortality rate for Black infants is three times higher than for white infants, so we need to identify what can be done to address staggering disparities within newborn care. Breast milk is the optimal nutrition source for vulnerable babies, but approximately 12% of neonatal intensive care units in California do not use donor milk. Donor milk is a covered benefit under Medi-Cal, but not under commercial plans. This bill will ensure parity and make it clear that donor milk is a covered health benefit for all babies that have a medical necessity. The author concludes that this bill will pave the way for better health outcomes for all vulnerable babies in California.
Arguments in Support
The UC, sponsor of this bill, writes that DHM has been used for decades to feed premature infants when their own parents' milk is not sufficient or cannot be used. DHM is used in the NICU to support the health and increase the survival of very low birth weight infants; it has been shown to reduce the incidence of a devastating bowel disease, known as NEC, compared to infant milk formula. Studies have shown that five to ten percent of VLBW babies develop NEC, which disproportionally impacts infants of color. The incidence of NEC is around 60% higher for Hispanic and Black infants when compared to white infants and can be reduced with adequate access to DHM. Expanding access to DHM will help close racial disparities in infant care. This bill would also address a challenge to establishing a DHM program in the requirement that hospitals obtain a tissue bank license to distribute the pasteurized donor milk. Under current law, the milk bank holds a tissue bank license and pasteurizes the milk, thus killing any live cells that can transmit disease. The DHM that arrives at hospitals no longer contains living cells, is ingested and should not be treated the same as tissues and organs. About 12% of NICUs in California do not use DHM, this bill will address this regulatory barrier by exempting hospitals from having to obtain a tissue bank license in order to distribute donor milk to infants in the NICU, setting California on a path of achieving 100% DHM usage in our NICUs.
Arguments in Opposition
The California Association of Health Plans (CAHP), the Association of California Life and Health Insurance Companies (ACLHIC), and America's Health Insurance Plans (AHIP) oppose mandates for health plans and insurers to cover specific services, as well as bills that eliminate cost sharing and limit utilization management, which have similar cost impacts as coverage mandates. Moreover, they will increase costs, reduce choice and competition, and further incent some employers and individuals to avoid state regulation by seeking alternative coverage options. These bills will lead to higher premiums, harming affordability and access for small businesses and individual market consumers. CAHP, ACLHIC, and AHIP write that state mandates increase costs of coverage, especially for families who buy coverage without subsidies, small business owners who cannot or do not wish to self-insure, and California taxpayers who foot the bill for the state's share of those mandates.
FISCAL COMMENTS
According to the Senate Appropriations Committee, the DMHC estimates costs of approximately $64,000 in 2025-26 and $133,000 in 2026-27 and annually thereafter for state administration (Managed Care Fund). CDI estimates one-time costs of $11,000 in 2024-25 for state administration (Insurance Fund). Unknown, potential ongoing General Fund costs for increased CalPERS health plan premiums.
VOTES:
ASM HEALTH: 16-0-0
YES: Bonta, Waldron, Aguiar-Curry, Arambula, Wendy Carrillo, Flora, Haney, Jones-Sawyer, Maienschein, McCarty, Joe Patterson, Rodriguez, Sanchez, Santiago, Schiavo, Weber
ASM APPROPRIATIONS: 15-0-0
YES: Wicks, Sanchez, Arambula, Bryan, Calderon, Wendy Carrillo, Dixon, Mike Fong, Grayson, Haney, Hart, Jim Patterson, Pellerin, Ta, Villapudua
ASSEMBLY FLOOR: 71-0-9
YES: Addis, Aguiar-Curry, Alanis, Alvarez, Arambula, Bains, Bauer-Kahan, Bennett, Berman, Boerner, Bonta, Bryan, Juan Carrillo, Wendy Carrillo, Chen, Connolly, Davies, Dixon, Flora, Mike Fong, Vince Fong, Gabriel, Gallagher, Garcia, Gipson, Grayson, Haney, Hart, Hoover, Irwin, Jackson, Jones-Sawyer, Kalra, Lackey, Lee, Low, Lowenthal, Maienschein, McCarty, McKinnor, Muratsuchi, Stephanie Nguyen, Ortega, Pacheco, Papan, Jim Patterson, Pellerin, Petrie-Norris, Quirk-Silva, Ramos, Rendon, Reyes, Rodriguez, Blanca Rubio, Sanchez, Santiago, Schiavo, Soria, Ta, Ting, Valencia, Villapudua, Waldron, Wallis, Ward, Weber, Wicks, Wilson, Wood, Zbur, Robert Rivas
ABS, ABST OR NV: Calderon, Cervantes, Megan Dahle, Essayli, Friedman, Holden, Mathis, Joe Patterson, Luz Rivas
SENATE FLOOR: 37-0-3
YES: Allen, Alvarado-Gil, Archuleta, Ashby, Atkins, Becker, Blakespear, Bradford, Caballero, Cortese, Dodd, Durazo, Eggman, Glazer, Gonzalez, Grove, Hurtado, Laird, Limón, McGuire, Menjivar, Min, Newman, Nguyen, Niello, Ochoa Bogh, Padilla, Portantino, Roth, Rubio, Skinner, Smallwood-Cuevas, Stern, Umberg, Wahab, Wiener, Wilk
ABS, ABST OR NV: Dahle, Jones, Seyarto
UPDATED
VERSION: August 20, 2024
CONSULTANT: Kristene Mapile / HEALTH / (916) 319-2097 FN: 0004313
SENATE RULES COMMITTEE Office of Senate Floor Analyses (916) 651-1520 Fax: (916) 327-4478 | AB 3059 |
THIRD READING
Bill No: AB 3059
Author: Weber (D), et al.
Amended: 8/20/24 in Senate
Vote: 21
SENATE HEALTH COMMITTEE: 11-0, 6/26/24
AYES: Roth, Nguyen, Glazer, Gonzalez, Grove, Hurtado, Limón, Menjivar, Rubio, Smallwood-Cuevas, Wiener
SENATE APPROPRIATIONS COMMITTEE: 4-1, 8/15/24
AYES: Caballero, Ashby, Becker, Wahab
NOES: Jones
NO VOTE RECORDED: Bradford, Seyarto
ASSEMBLY FLOOR: 71-0, 5/22/24 - See last page for vote
SUBJECT: Human milk
SOURCE: University of California
DIGEST:
This bill indicates that medically necessary pasteurized donor human milk obtained from a licensed tissue bank is a basic health care services, as defined. This bill exempts a general acute care hospital from the tissue bank licensure requirement for the storage or distribution of pasteurized donor human milk that meets standards by the Human Milk Banking Association of North America or other standards approved by the Department of Public Health.
Senate Floor Amendments of 8/20/24 clarify that medically necessary pasteurized donor human milk obtained from a licensed tissue bank is a basic health care service, as defined, and that a general acute care hospital that is exempt from tissue bank licensure for collecting, storing, or distributing human milk must meet standards by the Human Milk Banking Association of North America or other standards approved by the Department of Public Health.
ANALYSIS:
Existing law:
- Licenses and regulates health care facilities, including general acute care hospitals, through the California Department of Public Health (CDPH). [HSC §1250 et seq.]
- Requires every tissue bank operating in California to have a current and valid tissue bank license, and includes 11 specified exemptions, such as the collection, processing, storage, or distribution of human whole blood or its derivatives by licensed blood banks or any person exempt from licensure. [HSC §1635.1]
- Requires a hospital that collects, processes, stores, or distributes human milk collected from a mother exclusively for her own child to comply with the most current standards established for the collection, processing, storage, or distribution of human milk by the Human Milk Banking Association of North America until or unless CDPH approves alternative standards. Makes a hospital exempt from the tissue bank licensure requirements for the purpose of collecting, processing, storing, or distributing human milk collected from a mother exclusively for her own child. [HSC §1648]
- Indicates 2) and 3) above do not apply to any hospital that collects, processes, stores, or distributes milk from human milk banks or other outside sources. [HSC §1648]
- Makes human milk and human milk derivatives supplied by a mothers’ milk bank for human consumption a covered Medi-Cal service. Defines “mothers’ milk bank” as any person, firm, or corporation which engages in the not-for-profit procurement, processing, storage, distribution, or use of human milk, contributed by volunteer donors, in compliance with standards prescribed by the Human Milk Banking Association of Northern America (HMBANA). [WIC §14132.34]
- Establishes the Department of Managed Health Care (DMHC) to regulate health plans under the Knox-Keene Health Care Service Plan Act of 1975 (Knox-Keene Act); California Department of Insurance (CDI) to regulate health and other insurance; and, the Department of Health Care Services (DHCS) to administer the Medi-Cal program. [HSC §1340, et seq., INS §106, et seq., and WIC §14000, et seq.]
- Defines “basic health care services” as all of the following:
- Physician services, including consultation and referral;
- Hospital inpatient services and ambulatory care services;
- Diagnostic laboratory and therapeutic radiologic services;
- Home health services;
- Preventive health services;
- Emergency health care services, including ambulance and ambulance transport services and out-of-area coverage. Basic health care services includes ambulance and ambulance transport services provided through the 911 emergency response system; and,
- Hospice care, as specified. [HSC §1345, INS §10112.27 and 10112.281]
This bill:
- Makes medically necessary pasteurized donor human milk obtained from a licensed tissue bank a basic health care service, as defined.
- Requires a general acute care hospital that is exempt from the tissue bank licensure requirement in existing law for purposes of the storage or distribution of pasteurized donor human milk, to comply with the most current standards established for the collection, processing, storage, or distribution of human milk by HMBANA or other standards approved by CDPH.
- Deletes a provision that indicates the tissue bank license exemption does not apply to any hospital that collects, processes, stores, or distributes milk from human milk banks or other outside sources.
Comments
- Author’s statement. According to the author, “addressing disparities in health care means looking at access to life-saving nutrition. The mortality rate for Black infants is three times higher than for white infants, so we need to identify what can be done to address staggering disparities within newborn care. Breast milk is the optimal nutrition source for vulnerable babies, but approximately 12% of neonatal intensive care units in California do not use donor milk. Donor milk is a covered benefit under Medi-Cal, but not under commercial plans. This bill will ensure parity and make it clear that donor milk is a covered health benefit for all babies that have a medical necessity. This bill will pave the way for better health outcomes for all vulnerable babies in California.”
- Medi-Cal. According to donor milk guidance for providers published in May 2023 on the DHCS website, for Medi-Cal coverage a mother and infant must have one or more of the specified conditions, such as a mother is unable to breast feed due to medical conditions; the infant cannot tolerate or has medical contra-indications to using formulas including elemental formulas; the infant is born at a very low birthweight (less than 1500g) and very premature (less than 32 weeks gestation); or, the infant has a gastrointestinal anomaly, metabolic/digestive disorder, or recovery from intestinal surgery when digestive needs require additional support.Authorized providers who can prescribe pasteurized donor human milk are physicians and advance practice nurses, but this may also include state licensed nutritionists or registered dieticians under a physician’s supervision. Prescriptions must show the amount and frequency of the feedings, and should be for three ounces per unit, 35 ounces per day, and only good for 30 days. The age of the infant may be up to 12 months of age as is medically necessary and appropriate. There are two human milk banks listed in the guidance: one in San Jose and one in San Diego; and DHCS requires that human milk banks be accredited by HMBANA, a nonprofit professional association of milk banks. HMBANA issues safety guidelines on processed human donor milk for member banks.
- HMBANA standards. A January 2024 overview of HMBANA standards summarizes the safety measures that HMBANA-accredited milk banks utilize to ensure the safety and quality of pasteurized donor human milk. The public document provides background for clinicians, healthcare organizations, and public health agencies that are interested in learning more about HMBANA milk banking procedures. The complete version of HMBANA Standards for Donor Human Milk Banking is proprietary and is provided to each HMBANA-accredited member milk bank, along with accreditation documents and other tools. According to HMBANA, HMBANA accreditation provides evidence that a milk bank is compliant with HMBANA Standards and maintains a comprehensive system of preventive controls, safety checks, verifications, validations, and corrective actions. HMBANA accreditation audits consist of onsite inspections, plant walkthroughs, record audits, standard operating procedure and food safety plan review, sanitation assessments, staff training evaluations, mock recalls, critical control point audits, staff interviews, and additional rigorous safety evaluations. HMBANA auditors are certified preventive controls qualified individuals through the Food Safety Preventive Controls Alliance and receive additional auditor training on an annual basis. As part of this overview, “milk donor” is defined as a healthy lactating mother who voluntarily, without receiving remuneration from any part, donates her milk. Donor exclusions include smoking or use of tobacco products, alcohol consumption, illegal recreational drugs, use of cannabis products, at-risk sexual practices, as well as other exclusions. Milk may not be donated if it has been heat-treated in any way by the donor. Milk may be temporarily stored in the refrigerator for a maximum of 96 hours before being moved to the freezer for long-term storage. Milk expires one year from the date of collection.
- California Health Benefits Review Program (CHBRP) report. CHBRP reviewed this bill before it was amended on June 17, 2024 to limit the bill to pasteurized human milk, excluding human milk-derived fortifiers. The June 17, 2024 amendments expand the suppliers of pasteurized human donor milk to include non-HMBANA certified providers. According to CHBRP, the amended language would not require coverage of human milk-derived fortifiers, which would mean somewhat less utilization of those fortifiers and a decrease in the expected shift of related costs from providers to health insurers; thus, there would be a decrease in premiums. Amended language would mandate coverage of donor human milk from any state-licensed tissue bank (not just mother’s milk banks). The change would not be expected to alter utilization in the first year postmandate, but greater numbers of suppliers might increase utilization in following years. All portions of CHBRP’s analysis related to donor human milk remain relevant. CHBRPs findings are below:
- Coverage impacts and enrollees covered. In 2025, all of the 22.3 million Californians enrolled in state-regulated health insurance would have insurance subject to this bill. At baseline, CHBRP estimates that 39.13% of enrollees with health insurance subject to this bill have coverage for both donor human milk and human milk-derived fortifiers.
- Medical effectiveness. CHBRP found clear and convincing evidence that donor human milk is more effective than preterm formula in the prevention of necrotizing enterocolitis (NEC) and bronchopulmonary dysplasia (BPD) in preterm infants. CHBRP found limited evidence that donor human milk is not as effective as preterm formula for weight gain, and a preponderance of evidence that donor human milk is no more effective than preterm formula for the prevention of late-onset sepsis (LOS) in preterm infants. Additionally, conclusions were inconclusive regarding the effectiveness of fortifiers derived from human milk versus bovine milk on outcomes for preterm infants.
- Utilization. CHBRP estimates this bill would result in an additional 35 enrollees (1%) utilizing donor human milk. In the first year post mandate, CHBRP estimates this bill would lead to universal access to donor human milk in California through the removal of requirements for hospitals to be licensed as a tissue bank in order to provide donor human milk to patients.
- Public health. There would be a reduction in the average number of NEC and BPD cases (0.62 and 1.75 cases per year, respectively), as well as a corresponding reduction in length of hospital stays (18 days for medically-treated NEC; 50 days for surgically-treated NEC; 26 days for BPD). This estimate is supported by clear and convincing evidence that donor human milk is medically effective in preventing NEC and BPD in preterm infants and an estimated increase in utilization of donor human milk. CHBRP estimates this bill would lead to universal access to donor human milk in California through the removal of requirements for hospitals to be licensed as a tissue bank in order to provide donor human milk to their patients and through reimbursement of these treatments. This could reduce disparities in receipt of donor human milk between infants with an inpatient stay at a smaller hospital.
FISCAL EFFECT: Appropriation: No Fiscal Com.: Yes Local: Yes
According to the Senate Appropriations Committee,
- DMHC estimates costs of approximately $64,000 in 2025-26 and $133,000 in 2026-27 and annually thereafter for state administration (Managed Care Fund).
- CDI estimates one-time costs of $11,000 in 2024-25 for state administration (Insurance Fund).
- Unknown, potential ongoing General Fund costs for increased CalPERS health plan premiums.
SUPPORT: (Verified 8/8/24)
University of California (source)
American Academy of Pediatrics, California
American College of Obstetricians and Gynecologists District IX
BreastfeedLA
California Association of Public Hospitals & Health Systems
California Hospital Association
California Life Sciences
California Medical Association
California WIC Association
Children's Specialty Care Coalition
County of Santa Clara
Human Milk Banking Association of North America
Human Milk Connection
Prolacta Bioscience
Sharp Healthcare
UC San Diego's Human Milk Institute
OPPOSITION: (Verified 8/8/24)
America’s Health Insurance Plans
Association of California Life and Health Insurance Companies
California Association of Health Plans
ARGUMENTS IN SUPPORT: The University of California is the sponsor of this bill and writes that this bill will improve health outcomes for premature infants. Donor milk has been used for decades to feed premature infants when their own parents’ milk is not sufficient or cannot be used. The American Academy of Pediatrics recommends that all infants weighing less than 3.3 pounds (known as very low birth weight) be given donor milk if the parent is not able to provide sufficient milk. Donor milk is used in the neonatal intensive care units (NICU) to support the health and increase the survival of very low birth weight infants; it has been shown to reduce the incidence of a devastating bowel disease, known as NEC, compared to infant milk formula. Studies have shown that five to ten percent of very low birth weight babies develop NEC, which disproportionally affects infants of color. Donor milk is a covered benefit under Medi-Cal, but existing law does not clearly define it as a covered benefit under commercial health plans. This bill would ensure parity and require that all commercial health plans provide coverage for medically necessary donor milk. About 12% of NICUs in California do not use donor milk; this bill will address this regulatory barrier by exempting hospitals from having to obtain a tissue bank license in order to distribute donor milk to infants in the NICU, setting California on a path of achieving 100% donor milk usage in our NICUs. This bill will help address disparities in health care, enabling vulnerable babies and their families to access donor milk and increase the provision of life-changing nutrition at hospitals.
ARGUMENTS IN OPPOSITION: The California Association of Health Plans, Association of California Life and Health Insurance Companies, and America’s Health Insurance Plans write to oppose this bill because it is one of 14 health insurance mandate bills that will increase costs, reduce choice and competition, and further incent some employers and individuals to avoid state regulation by seeking alternative coverage options. Benefit mandates impose a one-size-fits-all approach to medical care and benefit design driven by the legislature rather than consumer choice. These bills will lead to higher premiums, harming affordability and access for small businesses and individual market consumers. These opponents urge legislators to also consider the cumulative impacts of these mandates on premiums and access to coverage. All of these bills will increase costs and limit employer flexibility. The Legislature created the Office of Health Care Affordability to contain cost drivers. With this office in place and the state budget deficit, the Legislature should take a wait-and-see approach when considering costly mandates. The health plans have continued to be engaged and look forward to the work ahead.
ASSEMBLY FLOOR: 71-0, 5/22/24
AYES: Addis, Aguiar-Curry, Alanis, Alvarez, Arambula, Bains, Bauer-Kahan, Bennett, Berman, Boerner, Bonta, Bryan, Juan Carrillo, Wendy Carrillo, Chen, Connolly, Davies, Dixon, Flora, Mike Fong, Vince Fong, Gabriel, Gallagher, Garcia, Gipson, Grayson, Haney, Hart, Hoover, Irwin, Jackson, Jones-Sawyer, Kalra, Lackey, Lee, Low, Lowenthal, Maienschein, McCarty, McKinnor, Muratsuchi, Stephanie Nguyen, Ortega, Pacheco, Papan, Jim Patterson, Pellerin, Petrie-Norris, Quirk-Silva, Ramos, Rendon, Reyes, Rodriguez, Blanca Rubio, Sanchez, Santiago, Schiavo, Soria, Ta, Ting, Valencia, Villapudua, Waldron, Wallis, Ward, Weber, Wicks, Wilson, Wood, Zbur, Robert Rivas
NO VOTE RECORDED: Calderon, Cervantes, Megan Dahle, Essayli, Friedman, Holden, Mathis, Joe Patterson, Luz Rivas
Prepared by: Teri Boughton / HEALTH / (916) 651-4111
8/21/24 16:12:33
**** END ****
SENATE RULES COMMITTEE Office of Senate Floor Analyses (916) 651-1520 Fax: (916) 327-4478 | AB 3059 |
THIRD READING
Bill No: AB 3059
Author: Weber (D), et al.
Amended: 6/17/24 in Senate
Vote: 21
SENATE HEALTH COMMITTEE: 11-0, 6/26/24
AYES: Roth, Nguyen, Glazer, Gonzalez, Grove, Hurtado, Limón, Menjivar, Rubio, Smallwood-Cuevas, Wiener
SENATE APPROPRIATIONS COMMITTEE: 4-1, 8/15/24
AYES: Caballero, Ashby, Becker, Wahab
NOES: Jones
NO VOTE RECORDED: Bradford, Seyarto
ASSEMBLY FLOOR: 71-0, 5/22/24 - See last page for vote
SUBJECT: Human milk
SOURCE: University of California
DIGEST:
This bill requires a health plan contract or health insurance policy, except for a specialized health plan contract or health insurance policy, to cover medically necessary pasteurized donor human milk obtained from a licensed tissue bank. This bill exempts a general acute care hospital from the tissue bank licensure requirement for the storage or distribution of pasteurized donor human milk that was obtained from a licensed tissue bank.
ANALYSIS:
Existing law:
- Licenses and regulates health care facilities, including general acute care hospitals, through the California Department of Public Health (CDPH). [HSC §1250 et seq.]
- Requires every tissue bank operating in California to have a current and valid tissue bank license, and includes 11 specified exemptions, such as the collection, processing, storage, or distribution of human whole blood or its derivatives by licensed blood banks or any person exempt from licensure. [HSC §1635.1]
- Defines “tissue bank” as a place, establishment, or institution that collects, processes, stores, or distributes tissue for transplantation into human beings, and, “transplantation” as the act or process of transferring tissue, including by ingestion, from a donor to the body of the donor or another human being. [HSC §1635]
- Requires the procurement, processing, distribution, or use of human milk for the purpose of human consumption to be construed to be, and is declared to be for all purposes, the rendition of a service by each and every nonprofit organization and its employees participating therein, and not construed to be, and declared not to be, a sale of the human milk for any purpose or purposes. [HSC §1647]
- Requires a hospital that collects, processes, stores, or distributes human milk collected from a mother exclusively for her own child to comply with the most current standards established for the collection, processing, storage, or distribution of human milk by the Human Milk Banking Association of North America until or unless CDPH approves alternative standards. Makes a hospital exempt from the tissue bank licensure requirements for the purpose of collecting, processing, storing, or distributing human milk collected from a mother exclusively for her own child. [HSC §1648]
- Prohibits screening tests from being required to be performed on human milk collected from a mother exclusively for her own child. Requires CDPH to assess hospital processes for collecting, processing, storing, or distributing human milk pursuant to its current practice. [HSC §1648]
- Indicates 5) and 6) above do not apply to any hospital that collects, processes, stores, or distributes milk from human milk banks or other outside sources. [HSC §1648]
- Makes human milk and human milk derivatives supplied by a mothers’ milk bank for human consumption a covered Medi-Cal service. Defines “mothers’ milk bank” as any person, firm, or corporation which engages in the not-for-profit procurement, processing, storage, distribution, or use of human milk, contributed by volunteer donors, in compliance with standards prescribed by the Human Milk Banking Association of Northern America (HMBANA). [WIC §14132.34]
- Establishes the Department of Managed Health Care (DMHC) to regulate health plans under the Knox-Keene Health Care Service Plan Act of 1975 (Knox-Keene Act); California Department of Insurance (CDI) to regulate health and other insurance; and, the Department of Health Care Services (DHCS) to administer the Medi-Cal program. [HSC §1340, et seq., INS §106, et seq., and WIC §14000, et seq.]
This bill:
- Requires a health plan contract or health insurance policy, except for a specialized health plan contract or health insurance policy that is issued, amended, delivered, or renewed on or after January 1, 2025, to cover medically necessary pasteurized donor human milk obtained from a licensed tissue bank.
- Exempts a general acute care hospital from the tissue bank licensure requirement in existing law for the storage or distribution of pasteurized donor human milk that was obtained from a licensed tissue bank.
Comments
- Author’s statement. According to the author, addressing disparities in health care means looking at access to life-saving nutrition. The mortality rate for Black infants is three times higher than for white infants, so we need to identify what can be done to address staggering disparities within newborn care. Breast milk is the optimal nutrition source for vulnerable babies, but approximately 12% of neonatal intensive care units in California do not use donor milk. Donor milk is a covered benefit under Medi-Cal, but not under commercial plans. This bill will ensure parity and make it clear that donor milk is a covered health benefit for all babies that have a medical necessity. This bill will pave the way for better health outcomes for all vulnerable babies in California.
- Medi-Cal. According to donor milk guidance for providers published in May 2023 on the DHCS website, for Medi-Cal coverage a mother and infant must have one or more of the following conditions:
- A mother is unable to breast feed due to medical conditions;
- The infant cannot tolerate or has medical contra-indications to using formulas including elemental formulas;
- The infant is born at a very low birthweight (less than 1500g) and very premature (less than 32 weeks gestation);
- The infant has a gastrointestinal anomaly, metabolic/digestive disorder, or recovery from intestinal surgery when digestive needs require additional support;
- The infant is diagnosed with failure to thrive (not appropriately gaining weight/growing);
- The infant has formula intolerance, with documented feeding difficulty or weight loss;
- The infant has hypoglycemia (low blood sugar); congenital heart disease, or is pre- or post-organ transplant;
- There are other serious health conditions when the use of banked donor human milk is medically necessary and supports the treatment and recovery of the infant; and/or,
- The mother’s milk is contraindicated, unavailable (due to medical or psychological condition), or available but lacking in quantity or quality to meet the infant’s needs.
Authorized providers who can prescribe pasteurized donor human milk are physicians and advance practice nurses, but this may also include state licensed nutritionists or registered dieticians under a physician’s supervision. Prescriptions must show the amount and frequency of the feedings, and should be for three ounces per unit, 35 ounces per day, and only good for 30 days. The age of the infant may be up to 12 months of age as is medically necessary and appropriate. There are two human milk banks listed in the guidance: one in San Jose and one in San Diego; and DHCS requires that human milk banks be accredited by HMBANA, a nonprofit professional association of milk banks. HMBANA issues safety guidelines on processed human donor milk for member banks.
- HMBANA standards. A January 2024 overview of HMBANA standards summarizes the safety measures that HMBANA-accredited milk banks utilize to ensure the safety and quality of pasteurized donor human milk. The public document provides background for clinicians, healthcare organizations, and public health agencies that are interested in learning more about HMBANA milk banking procedures. The complete version of HMBANA Standards for Donor Human Milk Banking is proprietary and is provided to each HMBANA-accredited member milk bank, along with accreditation documents and other tools. According to HMBANA, HMBANA accreditation provides evidence that a milk bank is compliant with HMBANA Standards and maintains a comprehensive system of preventive controls, safety checks, verifications, validations, and corrective actions. HMBANA accreditation audits consist of onsite inspections, plant walkthroughs, record audits, standard operating procedure and food safety plan review, sanitation assessments, staff training evaluations, mock recalls, critical control point audits, staff interviews, and additional rigorous safety evaluations. HMBANA auditors are certified preventive controls qualified individuals through the Food Safety Preventive Controls Alliance and receive additional auditor training on an annual basis. As part of this overview, “milk donor” is defined as a healthy lactating mother who voluntarily, without receiving remuneration from any part, donates her milk. Donor exclusions include smoking or use of tobacco products, alcohol consumption, illegal recreational drugs, use of cannabis products, at-risk sexual practices, as well as other exclusions. Milk may not be donated if it has been heat-treated in any way by the donor. Milk may be temporarily stored in the refrigerator for a maximum of 96 hours before being moved to the freezer for long-term storage. Milk expires one year from the date of collection.
- California Health Benefits Review Program (CHBRP) report. CHBRP reviewed this bill before it was amended on June 17, 2024 to limit the bill to pasteurized human milk, excluding human milk-derived fortifiers. The June 17, 2024 amendments expand the suppliers of pasteurized human donor milk to include non-HMBANA certified providers. According to CHBRP, the amended language would not require coverage of human milk-derived fortifiers, which would mean somewhat less utilization of those fortifiers and a decrease in the expected shift of related costs from providers to health insurers; thus, there would be a decrease in premiums. Amended language would mandate coverage of donor human milk from any state-licensed tissue bank (not just mother’s milk banks). The change would not be expected to alter utilization in the first year postmandate, but greater numbers of suppliers might increase utilization in following years. All portions of CHBRP’s analysis related to DHM remain relevant. CHBRPs findings are below:
- Coverage impacts and enrollees covered. In 2025, all of the 22.3 million Californians enrolled in state-regulated health insurance would have insurance subject to this bill. At baseline, CHBRP estimates that 39.13% of enrollees with health insurance subject to this bill have coverage for both donor human milk and human milk-derived fortifiers.
- Medical effectiveness. CHBRP found clear and convincing evidence that donor human milk is more effective than preterm formula in the prevention of necrotizing enterocolitis (NEC) and bronchopulmonary dysplasia (BPD) in preterm infants. CHBRP found limited evidence that donor human milk is not as effective as preterm formula for weight gain, and a preponderance of evidence that donor human milk is no more effective than preterm formula for the prevention of late-onset sepsis (LOS) in preterm infants. Additionally, conclusions were inconclusive regarding the effectiveness of fortifiers derived from human milk versus bovine milk on outcomes for preterm infants.
- Utilization. CHBRP estimates this bill would result in an additional 35 enrollees (1%) utilizing donor human milk. In the first year post mandate, CHBRP estimates this bill would lead to universal access to donor human milk in California through the removal of requirements for hospitals to be licensed as a tissue bank in order to provide donor human milk to patients.
- Medi-Cal. Insurance of Medi-Cal beneficiaries in DMHC-regulated plans would not be impacted due to full compliance at baseline.
- Impact on expenditures. In 2025, this bill results in, approximately, an additional $9,668,000 (0.00006%) in total net annual expenditures. This is inclusive of an approximate $8.6 million shift in expenses for donor human milk and human milk fortifiers from providers (hospitals) to health insurance subject to this bill, and cost offsets due to an estimated increase in prevented cases of NEC and BPD.
- Public health. There would be a reduction in the average number of NEC and BPD cases (0.62 and 1.75 cases per year, respectively), as well as a corresponding reduction in length of hospital stays (18 days for medically-treated NEC; 50 days for surgically-treated NEC; 26 days for BPD). This estimate is supported by clear and convincing evidence that donor human milk is medically effective in preventing NEC and BPD in preterm infants and an estimated increase in utilization of donor human milk. CHBRP estimates this bill would lead to universal access to donor human milk in California through the removal of requirements for hospitals to be licensed as a tissue bank in order to provide donor human milk to their patients and through reimbursement of these treatments. This could reduce disparities in receipt of donor human milk between infants with an inpatient stay at a smaller hospital.
- Essential health benefits. CHBRP believes this bill would not exceed the essential health benefits, which would require the state defray costs to health plans associated with this mandate as required by under the Affordable Care Act.
FISCAL EFFECT: Appropriation: No Fiscal Com.: Yes Local: Yes
According to the Senate Appropriations Committee,
- DMHC estimates costs of approximately $64,000 in 2025-26 and $133,000 in 2026-27 and annually thereafter for state administration (Managed Care Fund).
- CDI) estimates one-time costs of $11,000 in 2024-25 for state administration (Insurance Fund).
- Unknown, potential ongoing General Fund costs for increased CalPERS health plan premiums.
SUPPORT: (Verified 8/8/24)
University of California (source)
American Academy of Pediatrics, California
American College of Obstetricians and Gynecologists District IX
BreastfeedLA
California Association of Public Hospitals & Health Systems
California Hospital Association
California Life Sciences
California Medical Association
California WIC Association
Children's Specialty Care Coalition
County of Santa Clara
Human Milk Banking Association of North America
Human Milk Connection
Prolacta Bioscience
Sharp Healthcare
UC San Diego's Human Milk Institute
OPPOSITION: (Verified 8/8/24)
America’s Health Insurance Plans
Association of California Life and Health Insurance Companies
California Association of Health Plans
ARGUMENTS IN SUPPORT: The University of California is the sponsor of this bill and writes that this bill will improve health outcomes for premature infants. Donor milk has been used for decades to feed premature infants when their own parents’ milk is not sufficient or cannot be used. The American Academy of Pediatrics recommends that all infants weighing less than 3.3 pounds (known as very low birth weight) be given donor milk if the parent is not able to provide sufficient milk. Donor milk is used in the neonatal intensive care units (NICU) to support the health and increase the survival of very low birth weight infants; it has been shown to reduce the incidence of a devastating bowel disease, known as NEC, compared to infant milk formula. Studies have shown that five to ten percent of very low birth weight babies develop NEC, which disproportionally affects infants of color. Donor milk is a covered benefit under Medi-Cal, but existing law does not clearly define it as a covered benefit under commercial health plans. This bill would ensure parity and require that all commercial health plans provide coverage for medically necessary donor milk. About 12% of NICUs in California do not use donor milk; this bill will address this regulatory barrier by exempting hospitals from having to obtain a tissue bank license in order to distribute donor milk to infants in the NICU, setting California on a path of achieving 100% donor milk usage in our NICUs. This bill will help address disparities in health care, enabling vulnerable babies and their families to access donor milk and increase the provision of life-changing nutrition at hospitals.
ARGUMENTS IN OPPOSITION: The California Association of Health Plans, Association of California Life and Health Insurance Companies, and America’s Health Insurance Plans write to oppose this bill because it is one of 14 health insurance mandate bills that will increase costs, reduce choice and competition, and further incent some employers and individuals to avoid state regulation by seeking alternative coverage options. Benefit mandates impose a one-size-fits-all approach to medical care and benefit design driven by the legislature rather than consumer choice. These bills will lead to higher premiums, harming affordability and access for small businesses and individual market consumers. These opponents urge legislators to also consider the cumulative impacts of these mandates on premiums and access to coverage. All of these bills will increase costs and limit employer flexibility. The Legislature created the Office of Health Care Affordability to contain cost drivers. With this office in place and the state budget deficit, the Legislature should take a wait-and-see approach when considering costly mandates. The health plans have continued to be engaged and look forward to the work ahead.
ASSEMBLY FLOOR: 71-0, 5/22/24
AYES: Addis, Aguiar-Curry, Alanis, Alvarez, Arambula, Bains, Bauer-Kahan, Bennett, Berman, Boerner, Bonta, Bryan, Juan Carrillo, Wendy Carrillo, Chen, Connolly, Davies, Dixon, Flora, Mike Fong, Vince Fong, Gabriel, Gallagher, Garcia, Gipson, Grayson, Haney, Hart, Hoover, Irwin, Jackson, Jones-Sawyer, Kalra, Lackey, Lee, Low, Lowenthal, Maienschein, McCarty, McKinnor, Muratsuchi, Stephanie Nguyen, Ortega, Pacheco, Papan, Jim Patterson, Pellerin, Petrie-Norris, Quirk-Silva, Ramos, Rendon, Reyes, Rodriguez, Blanca Rubio, Sanchez, Santiago, Schiavo, Soria, Ta, Ting, Valencia, Villapudua, Waldron, Wallis, Ward, Weber, Wicks, Wilson, Wood, Zbur, Robert Rivas
NO VOTE RECORDED: Calderon, Cervantes, Megan Dahle, Essayli, Friedman, Holden, Mathis, Joe Patterson, Luz Rivas
Prepared by: Teri Boughton / HEALTH / (916) 651-4111
8/18/24 9:19:36
**** END ****
SENATE COMMITTEE ON
Senator Anna Caballero, Chair
2023 - 2024 Regular Session
AB 3059 (Weber) - Human milk
Version: | Policy Vote: |
Urgency: | Mandate: |
Hearing Date: | Consultant: |
Bill Summary:
AB 3059 would require health plans and insurers to cover medically necessary pasteurized donor human milk, as specified.
Fiscal Impact:
- The Department of Managed Health Care (DMHC) estimates costs of approximately $64,000 in 2025-26 and $133,000 in 2026-27 and annually thereafter for state administration (Managed Care Fund).
- The California Department of Insurance (CDI) estimates one-time costs of $11,000 in 2024-25 for state administration (Insurance Fund).
- Unknown, potential ongoing General Fund costs for increased CalPERS health plan premiums.
Background:
Current law requires every tissue bank operating in California to have a current and valid tissue bank license from the California Department of Public Health, and includes 11 specified exemptions, such as the collection, processing, storage, or distribution of human whole blood or its derivatives by licensed blood banks or any person exempt from licensure.
Current law makes human milk and human milk derivatives supplied by a mothers’ milk bank for human consumption a covered Medi-Cal service. Current law defines “mothers’ milk bank” as any person, firm, or corporation which engages in the not-for-profit procurement, processing, storage, distribution, or use of human milk, contributed by volunteer donors, in compliance with standards prescribed by the Human Milk Banking Association of Northern America (HMBANA). According to donor milk guidance for providers published in May 2023 on the Department of Health Care Services website, for Medi-Cal coverage a mother and infant must have one or more of the following conditions:
- A mother is unable to breast feed due to medical conditions;
- The infant cannot tolerate or has medical contra-indications to using formulas including elemental formulas;
- The infant is born at a very low birthweight (less than 1500g) and very premature (less than 32 weeks gestation);
- The infant has a gastrointestinal anomaly, metabolic/digestive disorder, or recovery from intestinal surgery when digestive needs require additional support;
- The infant is diagnosed with failure to thrive (not appropriately gaining weight/growing);
- The infant has formula intolerance, with documented feeding difficulty or weight loss;
- The infant has hypoglycemia (low blood sugar); congenital heart disease, or is pre- or post-organ transplant;
- There are other serious health conditions when the use of banked donor human milk is medically necessary and supports the treatment and recovery of the infant; and/or,
- The mother’s milk is contraindicated, unavailable (due to medical or psychological condition), or available but lacking in quantity or quality to meet the infant’s needs.
Authorized providers who can prescribe pasteurized donor human milk are physicians and advance practice nurses, but this may also include state licensed nutritionists or registered dieticians under a physician’s supervision. Prescriptions must show the amount and frequency of the feedings, and should be for three ounces per unit, 35 ounces per day, and only good for 30 days. The age of the infant may be up to 12 months of age as is medically necessary and appropriate.
Proposed Law:
Specific provisions of the bill would:
- Require health plans and insurers to cover medically necessary pasteurized donor human milk obtained from a licensed tissue bank, as specified.
- Exempt a general acute care hospital from the tissue bank licensure requirement in existing law for the storage or distribution of pasteurized donor human milk that was obtained from a licensed tissue bank.
Staff Comments:
The California Health Benefits Review Program (CHBRP) analysis of AB 3059 (June 17, 2024 version) estimates an increase of $2,225,000 in total annual expenditures, including changes in total premiums paid by employers and enrollees of
DMHC-regulated plans and CDI-regulated policies of newly covered benefits. Total
CalPERS employer premiums would increase by $132,000.
-- END --
SENATE COMMITTEE ON HEALTH
Senator Richard Roth, Chair
BILL NO: AB 3059
AUTHOR: | Weber | ||
VERSION: | June 17, 2024 | ||
HEARING DATE: | June 26, 2024 | ||
CONSULTANT: | Teri Boughton | ||
SUBJECT: Human milk
SUMMARY:
Requires a health plan contract or health insurance policy, except for a specialized health plan contract or health insurance policy, to cover medically necessary pasteurized donor human milk obtained from a licensed tissue bank. Exempts a general acute care hospital from the tissue bank licensure requirement for the storage or distribution of pasteurized donor human milk that was obtained from a licensed tissue bank.
Existing law:
- Licenses and regulates health care facilities, including general acute care hospitals, through the California Department of Public Health (CDPH). [HSC §1250 et seq.]
- Requires every tissue bank operating in California to have a current and valid tissue bank license, and includes 11 specified exemptions, such as the collection, processing, storage, or distribution of human whole blood or its derivatives by licensed blood banks or any person exempt from licensure. [HSC §1635.1]
- Defines “tissue bank” as a place, establishment, or institution that collects, processes, stores, or distributes tissue for transplantation into human beings, and, “transplantation” as the act or process of transferring tissue, including by ingestion, from a donor to the body of the donor or another human being. [HSC §1635]
- Requires the procurement, processing, distribution, or use of human milk for the purpose of human consumption to be construed to be, and is declared to be for all purposes, the rendition of a service by each and every nonprofit organization and its employees participating therein, and not construed to be, and declared not to be, a sale of the human milk for any purpose or purposes. [HSC §1647]
- Requires a hospital that collects, processes, stores, or distributes human milk collected from a mother exclusively for her own child to comply with the most current standards established for the collection, processing, storage, or distribution of human milk by the Human Milk Banking Association of North America until or unless CDPH approves alternative standards. Makes a hospital exempt from the tissue bank licensure requirements for the purpose of collecting, processing, storing, or distributing human milk collected from a mother exclusively for her own child. [HSC §1648]
- Prohibits screening tests from being required to be performed on human milk collected from a mother exclusively for her own child. Requires CDPH to assess hospital processes for collecting, processing, storing, or distributing human milk pursuant to its current practice. [HSC §1648]
- Indicates 5) and 6) above do not apply to any hospital that collects, processes, stores, or distributes milk from human milk banks or other outside sources. [HSC §1648]
- Makes human milk and human milk derivatives supplied by a mothers’ milk bank for human consumption a covered Medi-Cal service. Defines “mothers’ milk bank” as any person, firm, or corporation which engages in the not-for-profit procurement, processing, storage, distribution, or use of human milk, contributed by volunteer donors, in compliance with standards prescribed by the Human Milk Banking Association of Northern America (HMBANA). [WIC §14132.34]
- Establishes the Department of Managed Health Care (DMHC) to regulate health plans under the Knox-Keene Health Care Service Plan Act of 1975 (Knox-Keene Act); California Department of Insurance (CDI) to regulate health and other insurance; and, the Department of Health Care Services (DHCS) to administer the Medi-Cal program. [HSC §1340, et seq., INS §106, et seq., and WIC §14000, et seq.]
This bill:
- Requires a health plan contract or health insurance policy, except for a specialized health plan contract or health insurance policy that is issued, amended, delivered, or renewed on or after January 1, 2025, to cover medically necessary pasteurized donor human milk obtained from a licensed tissue bank.
- Exempts a general acute care hospital from the tissue bank licensure requirement in existing law for the storage or distribution of pasteurized donor human milk that was obtained from a licensed tissue bank.
FISCAL EFFECT:
According to the Assembly Appropriations Committee:
- Annual costs of about $332,000 for California Public Enrollees’ Retirement System (CalPERS) enrollees in plans regulated by the DMHC (Public Employees Health Care Fund, special funds). The California Health Benefits Review Program (CHBRP) estimates premiums for CalPERS enrollees in DMHC would increase by $553,000; of which the State pays approximately 60%.
- DMHC estimates the total cost of this bill to be approximately $64,000 in fiscal year (FY) 2025-26 and $133,000 in FY 2026-27 and annually thereafter (Managed Care Fund). DMHC’s Office of Plan Monitoring (OPM) anticipates additional workload to develop and maintain survey methodologies and provide clinical and statistical review during routine and follow up survey activities for compliance with the requirements set forth in this bill.
- Costs of $11,000 in FY 2024-25 to the CDI (Insurance Fund).
- Minor and absorbable costs to CDPH.
PRIOR VOTES:
Assembly Floor: | 71 - 0 |
Assembly Appropriations Committee: | 15 - 0 |
Assembly Health Committee: | 16 - 0 |
COMMENTS:
- Author’s statement. According to the author, addressing disparities in health care means looking at access to life-saving nutrition. The mortality rate for Black infants is three times higher than for white infants, so we need to identify what can be done to address staggering disparities within newborn care. Breast milk is the optimal nutrition source for vulnerable babies, but approximately 12% of neonatal intensive care units in California do not use donor milk. Donor milk is a covered benefit under Medi-Cal, but not under commercial plans. This bill will ensure parity and make it clear that donor milk is a covered health benefit for all babies that have a medical necessity. This bill will pave the way for better health outcomes for all vulnerable babies in California.
- Medi-Cal. According to donor milk guidance for providers published in May 2023 on the DHCS website, for Medi-Cal coverage a mother and infant must have one or more of the following conditions:
- A mother is unable to breast feed due to medical conditions;
- The infant cannot tolerate or has medical contra-indications to using formulas including elemental formulas;
- The infant is born at a very low birthweight (less than 1500g) and very premature (less than 32 weeks gestation);
- The infant has a gastrointestinal anomaly, metabolic/digestive disorder, or recovery from intestinal surgery when digestive needs require additional support;
- The infant is diagnosed with failure to thrive (not appropriately gaining weight/growing);
- The infant has formula intolerance, with documented feeding difficulty or weight loss;
- The infant has hypoglycemia (low blood sugar); congenital heart disease, or is pre- or post-organ transplant;
- There are other serious health conditions when the use of banked donor human milk is medically necessary and supports the treatment and recovery of the infant; and/or,
- The mother’s milk is contraindicated, unavailable (due to medical or psychological condition), or available but lacking in quantity or quality to meet the infant’s needs.
Authorized providers who can prescribe pasteurized donor human milk are physicians and advance practice nurses, but this may also include state licensed nutritionists or registered dieticians under a physician’s supervision. Prescriptions must show the amount and frequency of the feedings, and should be for three ounces per unit, 35 ounces per day, and only good for 30 days. The age of the infant may be up to 12 months of age as is medically necessary and appropriate. There are two human milk banks listed in the guidance: one in San Jose and one in San Diego; and DHCS requires that human milk banks be accredited by HMBANA, a nonprofit professional association of milk banks. HMBANA issues safety guidelines on processed human donor milk for member banks.
- HMBANA standards. A January 2024 overview of HMBANA standards summarizes the safety measures that HMBANA-accredited milk banks utilize to ensure the safety and quality of pasteurized donor human milk. The public document provides background for clinicians, healthcare organizations, and public health agencies that are interested in learning more about HMBANA milk banking procedures. The complete version of HMBANA Standards for Donor Human Milk Banking is proprietary and is provided to each HMBANA-accredited member milk bank, along with accreditation documents and other tools. According to HMBANA, HMBANA accreditation provides evidence that a milk bank is compliant with HMBANA Standards and maintains a comprehensive system of preventive controls, safety checks, verifications, validations, and corrective actions. HMBANA accreditation audits consist of onsite inspections, plant walkthroughs, record audits, standard operating procedure and food safety plan review, sanitation assessments, staff training evaluations, mock recalls, critical control point audits, staff interviews, and additional rigorous safety evaluations. HMBANA auditors are certified preventive controls qualified individuals through the Food Safety Preventive Controls Alliance and receive additional auditor training on an annual basis. As part of this overview, “milk donor” is defined as a healthy lactating mother who voluntarily, without receiving remuneration from any part, donates her milk. Donor exclusions include smoking or use of tobacco products, alcohol consumption, illegal recreational drugs, use of cannabis products, at-risk sexual practices, as well as other exclusions. Milk may not be donated if it has been heat-treated in any way by the donor. Milk may be temporarily stored in the refrigerator for a maximum of 96 hours before being moved to the freezer for long-term storage. Milk expires one year from the date of collection.
- California Health Benefits Review Program (CHBRP) report. AB 1996 (Thomson, Chapter 795, Statutes of 2002) requests the University of California to assess legislation proposing a mandated benefit or service and prepare a written analysis with relevant data on the medical, economic, and public health impacts of proposed health plan and health insurance benefit mandate legislation. CHBRP was created in response to AB 1996, and reviewed this bill before it was amended on June 17, 2024 to limit the bill to pasteurized human milk, excluding human milk-derived fortifiers. The amendments expand the suppliers of pasteurized human donor milk to include non-HMBANA certified providers. These amendments many have an impact on CHBRPs findings below:
- Coverage impacts and enrollees covered. In 2025, all of the 22.3 million Californians enrolled in state-regulated health insurance would have insurance subject to this bill. At baseline, CHBRP estimates that 39.13% of enrollees with health insurance subject to this bill have coverage for both donor human milk and human milk-derived fortifiers.
- Medical effectiveness. CHBRP found clear and convincing evidence that donor human milk is more effective than preterm formula in the prevention of necrotizing enterocolitis (NEC) and bronchopulmonary dysplasia (BPD) in preterm infants. CHBRP found limited evidence that donor human milk is not as effective as preterm formula for weight gain, and a preponderance of evidence that donor human milk is no more effective than preterm formula for the prevention of late-onset sepsis (LOS) in preterm infants. Additionally, conclusions were inconclusive regarding the effectiveness of fortifiers derived from human milk versus bovine milk on outcomes for preterm infants.
- Utilization. CHBRP estimates this bill would result in an additional 35 enrollees (1%) utilizing donor human milk. In the first year post mandate, CHBRP estimates this bill would lead to universal access to donor human milk in California through the removal of requirements for hospitals to be licensed as a tissue bank in order to provide donor human milk to patients.
- Medi-Cal. Insurance of Medi-Cal beneficiaries in DMHC-regulated plans would not be impacted due to full compliance at baseline.
- Impact on expenditures. In 2025, this bill would result in, approximately, an additional $9,668,000 (0.00006%) in total net annual expenditures. This is inclusive of an approximate $8.6 million shift in expenses for donor human milk and human milk fortifiers from providers (hospitals) to health insurance subject to this bill, and cost offsets due to an estimated increase in prevented cases of NEC and BPD.
- Public health. There would be a reduction in the average number of NEC and BPD cases (0.62 and 1.75 cases per year, respectively), as well as a corresponding reduction in length of hospital stays (18 days for medically-treated NEC; 50 days for surgically-treated NEC; 26 days for BPD). This estimate is supported by clear and convincing evidence that donor human milk is medically effective in preventing NEC and BPD in preterm infants and an estimated increase in utilization of donor human milk. CHBRP estimates this bill would lead to universal access to donor human milk in California through the removal of requirements for hospitals to be licensed as a tissue bank in order to provide donor human milk to their patients and through reimbursement of these treatments. This could reduce disparities in receipt of donor human milk between infants with an inpatient stay at a smaller hospital.
- Essential health benefits. CHBRP believes this bill would not exceed the essential health benefits, which would require the state defray costs to health plans associated with this mandate as required by under the Affordable Care Act.
- Prior legislation. SB 1316 (Wolk of 2016) would have: required a tissue bank to comply with HMBANA guidelines, and disclose to a mother who is considering providing human milk to a tissue bank the purposes for which the procured milk is used; prohibited a tissue bank that provides payment to a mother for human milk from using the term “community benefit” to describe itself or its activities; and, required CDPH to adopt regulations governing tissue bank licensing related to human milk that are substantially based on HMBANA guidelines. SB 1316 was held on the Senate Appropriations Committee suspense file.
- Support. The University of California is the sponsor of this bill and writes that this bill will improve health outcomes for premature infants. Donor milk has been used for decades to feed premature infants when their own parents’ milk is not sufficient or cannot be used. The American Academy of Pediatrics recommends that all infants weighing less than 3.3 pounds (known as very low birth weight) be given donor milk if the parent is not able to provide sufficient milk. Donor milk is used in the neonatal intensive care units (NICU) to support the health and increase the survival of very low birth weight infants; it has been shown to reduce the incidence of a devastating bowel disease, known as NEC, compared to infant milk formula. Studies have shown that five to ten percent of very low birth weight babies develop NEC, which disproportionally affects infants of color. Donor milk is a covered benefit under Medi-Cal, but existing law does not clearly define it as a covered benefit under commercial health plans. This bill would ensure parity and require that all commercial health plans provide coverage for medically necessary donor milk. About 12% of NICUs in California do not use donor milk; this bill will address this regulatory barrier by exempting hospitals from having to obtain a tissue bank license in order to distribute donor milk to infants in the NICU, setting California on a path of achieving 100% donor milk usage in our NICUs. This bill will help address disparities in health care, enabling vulnerable babies and their families to access donor milk and increase the provision of life-changing nutrition at hospitals.
- Opposition. The California Association of Health Plans, Association of California Life and Health Insurance Companies, and America’s Health Insurance Plans write to oppose this bill because it is one of 14 health insurance mandate bills that will increase costs, reduce choice and competition, and further incent some employers and individuals to avoid state regulation by seeking alternative coverage options. Benefit mandates impose a one-size-fits-all approach to medical care and benefit design driven by the legislature rather than consumer choice. These bills will lead to higher premiums, harming affordability and access for small businesses and individual market consumers. These opponents urge legislators to also consider the cumulative impacts of these mandates on premiums and access to coverage. All of these bills will increase costs and limit employer flexibility. The Legislature created the Office of Health Care Affordability to contain cost drivers. With this office in place and the state budget deficit, the Legislature should take a wait-and-see approach when considering costly mandates. The health plans have continued to be engaged and look forward to the work ahead. Individuals
SUPPORT AND OPPOSITION:
Support: University of California (sponsor)
American Academy of Pediatrics, California
American College of Obstetricians and Gynecologists District IX
BreastfeedLA
California Association of Public Hospitals & Health Systems
California Hospital Association
California Life Sciences
California Medical Association
California WIC Association
Children's Specialty Care Coalition
County of Santa Clara
Human Milk Banking Association of North America
Human Milk Connection
Prolacta Bioscience
Sharp Healthcare
UC San Diego's Human Milk Institute
Oppose: America’s Health Insurance Plans
Association of California Life and Health Insurance Companies
California Association of Health Plans
-- END --
ASSEMBLY THIRD READING
ATR Bill Id:AB 3059
Author:(Weber)
As Amended Ver:March 11, 2024
Majority vote
SUMMARY
Requires a health plan contract or insurance policy, as specified, to cover the same health benefits for human milk and human milk derivatives covered under the Medi-Cal program as of 1988. Exempts from tissue bank licensure, the storage or distribution of pasteurized human milk that was obtained from a mothers’ milk bank, as defined, by a general acute care hospital (GACH).
Major Provisions
COMMENTS
The American Academy of Pediatrics (AAP) recommends exclusive feeding with human milk for the first six months of life, with the continuation of feeding for 1 year or longer as mutually desired by mother and infant. In addition, the AAP recommends that when mother's own milk is not available that donor human milk (DHM) be provided to all preterm and low-birthweight. DHM is provided through human milk banks that collect DHM, screen it for disease, pasteurize it, and freeze it for distribution to hospitals for use in the neonatal intensive care unit (NICU) setting. Necrotizing Enterocolitis is a severe disease of the intestinal tract and is one of the main causes of morbidity and mortality among very low–birthweight (VLBW) infants.
- Tissue bank requirements. All California hospitals that collect, process, store, or distribute human milk collected from a mother exclusively for her own child must follow Human Milk Banking Association of North America (HMBANA) standards. The Department of Public Health (DPH) requires all hospitals that store DHM to hold a tissue bank license. California law defines a tissue bank as a place, establishment, or institution that collects, processes, stores, or distributes tissue for transplantation into human beings. California requires tissue banks operating in California on or after July 1, 1992, to have a current and valid tissue bank license from DPH. The law includes exemptions for certain procedures; however, the storage or distribution of pasteurized human milk is not among them. California milk banks that meet the state's statutory definition of a mothers' milk bank that applied for a tissue bank license before January 1, 1995, are exempt from the application and annual renewal fee for a tissue bank license. There are two milk banks that meet the state's definition of a mothers' milk bank: Mothers’ Milk Bank in San Jose was founded in 1974, and the University of California (UC) Health Milk Bank was founded in 2020. The UC Health Milk Bank is required to hold a valid tissue bank license to operate, whereas the Mothers' Milk Bank in San Jose is exempt.
According to the author, milk banks that collect and process unpasteurized milk should have a tissue bank license, while hospitals that are only storing and distributing the pasteurized donor milk product should not. California currently exempts hospitals from obtaining a tissue bank license for the purpose of collecting, processing, storing or distributing human milk collected from a mother exclusively for her own child. Hospitals follow the same safety protocols for storing and distributing pasteurized DHM as a mother's own milk. This bill exempts the storage or distribution of DHM in a GACH from tissue bank licensure.
- Medi-Cal coverage of donor milk. Since 1998, California law has required the state's Medi-Cal program to provide coverage for DHM and human milk derivatives supplied by a mothers' milk bank for human consumption. Although the law does not define "human milk," "human milk derivatives," or details on coverage requirements, the Department of Health Care Services (DHCS) published a policy letter highlighting the importance of breastfeeding for mothers and infants. The policy letter further specified that the timely provision of human milk must be covered if "a mother is unable to breastfeed due to medical reasons, and the infant cannot tolerate or has medical contraindications to the use of any formula, including elemental formulas." In a May 2023 billing code update, DHCS described Medi-Cal eligibility and noted that mother and infant must have one or more of the following conditions:
- A mother is unable to breast feed due to medical conditions;
- The infant cannot tolerate or has medical contraindications to using formulas including elemental formulas;
- The infant is born at a VLBW (less than1500 g) and very premature (less than 32 weeks gestation);
- Gastrointestinal anomaly, metabolic/digestive disorder, or recovery from intestinal surgery when digestive needs require additional support;
- Diagnosed with failure to thrive (not appropriately gaining weight/growing);
- Formula intolerance, with documented feeding difficulty or weight loss;
- Infant hypoglycemia (low blood sugar); congenital heart disease, pre or post organ transplant;
- Other serious health conditions when the use of banked DHM is medically necessary and supports the treatment and recovery of the infant; and,
- The mother's milk must be contraindicated, unavailable (due to medical or psychological condition), or available but lacking in quantity or quality to meet the infant's needs.
Prescriptions must show the amount and frequency of the feedings, three ounces per unit, 35 ounces per day only good for 30 days. Coverage may be up to 12 months of age as is medically necessary and appropriate. Human milk banks must be accredited by the HMBANA, a nonprofit professional association of milk banks. HMBANA issues safety guidelines on processed DHM for member banks.
- California Health Benefits Review Program (CHBRP) analysis. CHBRP's analysis of this bill includes the following:
- Assumptions. This bill would affect coverage of two health services: DHM and human milk-derived fortifiers (HMF). At baseline, CHBRP estimates that 39.13% of enrollees with health insurance subject to this bill have coverage for DHM and HMF. Postmandate, CHBRP estimates that 100% of enrollees with health insurance subject to this bill would have coverage for these benefits.
- Impact on expenditures. In 2025, this bill would result in, approximately, an additional $9,668,000 (0.00006%) in total net annual expenditures. This is inclusive of an approximate $8.6 million shift in expenses for DHM and HMF from providers (hospitals) to health insurance subject to this bill, and cost offsets due to an estimated increase in prevented cases of NEC and Bronchopulmanary Dysplasia (BPD). CHBRP estimates this bill would result in an additional 35 enrollees (1%) utilizing DHM and an additional 11 enrollees utilizing HMF. In the first year postmandate, CHBRP estimates this bill would lead to universal access to DHM in California through the removal of requirements for hospitals to be licensed as a tissue bank in order to provide DHM to patients, and that there would be a reduction in the average number of NEC and BPD cases of 0.62 and 1.75 cases per year, respectively, as well as a corresponding reduction in length of hospital stay (18 days for medically treated NEC; 50 days for surgically-treated NEC; 26 days for BPD).
- Premiums for enrollees in individual plans purchased through Covered California would increase by a total of $1,307,000 in annual expenditures, a 0.0083% increase.
- Medi-Cal. At baseline, Medi-Cal beneficiaries in the Department of Managed Health Care (DMHC)-regulated plans have 100% coverage for human milk and human milk derivatives. In DMHC-regulated Medi-Cal plans, total premiums would decrease by $36,000 (0.0001%).
- CalPERS. For enrollees associated with the California Public Enrollees' Retirement System (CalPERS) in DMHC-regulated plans, premiums would increase by 0.0079% ($0.0621 per member per month, or $553,000 total increase in expenditures).
- Number of Uninsured in California. CHBRP estimates this bill would have no measurable impact on the number of uninsured persons.
- Essential Health Benefits (EHBs). In California, nongrandfathered individual and small-group health insurance is generally required to cover EHBs. According to CHBRP, this bill would not appear to exceed the definition of EHBs in California.
- Public health. In the first year postmandate, CHBRP estimates that there would be a reduction in the average number of NEC and BPD cases per year, respectively, as well as a corresponding reduction in length of hospital stay (18 days for medically-treated NEC; 50 days for surgically-treated NEC; 26 days for BPD). This estimate is supported by clear and convincing evidence that DHM is medically effective in preventing NEC and BPD in preterm infants and an estimated increase in utilization (1%) of DHM. CHBRP estimates this bill would lead to universal access to DHM in California through the removal of requirements for hospitals to be licensed as a tissue bank in order to provide DHM to their patients and through reimbursement of these treatments. This could reduce disparities in receipt of DHM between infants with an inpatient stay at a smaller hospital.
- Assumptions. This bill would affect coverage of two health services: DHM and human milk-derived fortifiers (HMF). At baseline, CHBRP estimates that 39.13% of enrollees with health insurance subject to this bill have coverage for DHM and HMF. Postmandate, CHBRP estimates that 100% of enrollees with health insurance subject to this bill would have coverage for these benefits.
According to the Author
Addressing disparities in health care means looking at access to life-saving nutrition. The mortality rate for Black infants is three times higher than for white infants, so we need to identify what can be done to address staggering disparities within newborn care. Breast milk is the optimal nutrition source for vulnerable babies, but approximately 12% of neonatal intensive care units in California do not use donor milk. Donor milk is a covered benefit under Medi-Cal, but not under commercial plans. This bill will ensure parity and make it clear that donor milk is a covered health benefit for all babies that have a medical necessity. The author concludes that this bill will pave the way for better health outcomes for all vulnerable babies in California.
Arguments in Support
The UC, sponsor of this bill, writes that DHM has been used for decades to feed premature infants when their own parents' milk is not sufficient or cannot be used. DHM is used in the NICU to support the health and increase the survival of very low birth weight infants; it has been shown to reduce the incidence of a devastating bowel disease, known as NEC, compared to infant milk formula. Studies have shown that five to ten percent of VLBW babies develop NEC, which disproportionally impacts infants of color. The incidence of NEC is around 60% higher for Hispanic and Black infants when compared to white infants and can be reduced with adequate access to DHM. Expanding access to DHM will help close racial disparities in infant care. This bill would also address a challenge to establishing a DHM program in the requirement that hospitals obtain a tissue bank license to distribute the pasteurized donor milk. Under current law, the milk bank holds a tissue bank license and pasteurizes the milk, thus killing any live cells that can transmit disease. The DHM that arrives at hospitals no longer contains living cells, is ingested and should not be treated the same as tissues and organs. About 12% of NICUs in California do not use DHM, this bill will address this regulatory barrier by exempting hospitals from having to obtain a tissue bank license in order to distribute donor milk to infants in the NICU, setting California on a path of achieving 100% DHM usage in our NICUs.
Arguments in Opposition
The California Association of Health Plans (CAHP), the Association of California Life and Health Insurance Companies (ACLHIC), and America’s Health Insurance Plans (AHIP) oppose mandates for health plans and insurers to cover specific services, as well as bills that eliminate cost sharing and limit utilization management, which have similar cost impacts as coverage mandates. Moreover, they will increase costs, reduce choice and competition, and further incent some employers and individuals to avoid state regulation by seeking alternative coverage options. These bills will lead to higher premiums, harming affordability and access for small businesses and individual market consumers. CAHP, ACLHIC, and AHIP write that state mandates increase costs of coverage, especially for families who buy coverage without subsidies, small business owners who cannot or do not wish to self-insure, and California taxpayers who foot the bill for the state’s share of those mandates.
FISCAL COMMENTS
- According to the Assembly Appropriations Committee, annual costs of about $332,000 for CalPERS enrollees in plans regulated by DMHC (Public Employees Health Care Fund, special funds). CHBRP estimates premiums for CalPERS enrollees in DMHC would increase by $553,000; of which the State pays approximately 60%.
- DMHC estimates the total cost of this bill to be approximately $64,000 in fiscal year (FY) 2025-26 and $133,000 in FY 2026-27 and annually thereafter (Managed Care Fund). DMHC’s Office of Plan Monitoring anticipates additional workload to develop and maintain survey methodologies and provide clinical and statistical review during routine and follow up survey activities for compliance with the requirements set forth in this bill.
- Costs of $11,000 in FY 2024-25 to the California Department of Insurance (Insurance Fund).
- Minor and absorbable costs to DPH.
VOTES
ASM HEALTH: 16-0-0
YES: Bonta, Waldron, Aguiar-Curry, Arambula, Wendy Carrillo, Flora, Haney, Jones-Sawyer, Maienschein, McCarty, Joe Patterson, Rodriguez, Sanchez, Santiago, Schiavo, Weber
ASM APPROPRIATIONS: 15-0-0
YES: Wicks, Sanchez, Arambula, Bryan, Calderon, Wendy Carrillo, Dixon, Mike Fong, Grayson, Haney, Hart, Jim Patterson, Pellerin, Ta, Villapudua
UPDATED
VERSION: March 11, 2024
CONSULTANT: Kristene Mapile / HEALTH / (916) 319-2097 FN: 0003365
Date of Hearing: May 8, 2024
ASSEMBLY COMMITTEE ON APPROPRIATIONS
Buffy Wicks, Chair
ABPCA Bill Id:AB 3059
Author:(Weber) – As Amended Ver:March 11, 2024
Policy Committee: | Health | Vote: | 16 - 0 |
|
| ||
|
|
Urgency: No State Mandated Local Program: Yes Reimbursable: No
SUMMARY:
This bill requires a health plan contract or health insurance policy to cover the same health benefits for human milk and human milk derivatives covered under the Medi-Cal program. The bill also exempts from tissue bank licensing requirements the storage or distribution in a hospital of human milk from a mother’s milk bank.
- Annual costs of about $332,000 for California Public Enrollees’ Retirement System (CalPERS) enrollees in plans regulated by the Department of Managed Health Care (DMHC) (Public Employees Health Care Fund, special funds). The California Health Benefits Review Program (CHBRP) estimates premiums for CalPERS enrollees in DMHC would increase by $553,000; of which the State pays approximately 60%.
- DMHC estimates the total cost of this bill to be approximately $64,000 in fiscal year (FY) 2025-26 and $133,000 in FY 2026-27 and annually thereafter (Managed Care Fund). DMHC’s Office of Plan Monitoring (OPM) anticipates additional workload to develop and maintain survey methodologies and provide clinical and statistical review during routine and follow up survey activities for compliance with the requirements set forth in this bill.
- Costs of $11,000 in FY 2024-25 to the Department of Insurance (Insurance Fund).
- Minor and absorbable costs to the California Department of Public Health (CDPH).
COMMENTS:
- Purpose. The sponsor of this bill is the University of California (UC). According to the author:
Addressing disparities in health care means looking at access to life-saving nutrition. The mortality rate for Black infants is three times higher than for white infants, so we need to identify what can be done to address staggering disparities within newborn care. Breast milk is the optimal nutrition source for vulnerable babies, but approximately 12% of neonatal intensive care units in California do not use donor milk. Donor milk is a covered benefit under Medi-Cal, but not under commercial plans. AB 3059 will ensure parity and make it clear that donor milk is a covered health benefit for all babies that have a medical necessity. AB 3059 will pave the way for better health outcomes for all vulnerable babies in California.
- Background. The American Academy of Pediatrics (AAP) recommends exclusive feeding with human milk for the first six months of life, with the continuation of feeding for one year or longer as desired by mother and infant. In addition, the AAP recommends that when a mother’s own milk is not available, donor human milk (DHM) be provided to all preterm and low-birthweight infants. DHM is provided through human milk banks that collect, screen for disease, pasteurize it, and freeze DHM for distribution to hospitals for use in the neonatal intensive care unit (NICU) setting.
Tissue Bank Requirements. All California hospitals that collect, process, store, or distribute human milk collected from a mother exclusively for her own child must follow Human Milk Banking Association of North America (HMBANA) standards. CDPH requires every hospital that stores DHM to hold a tissue bank license. Tissue is defined to include, among other things, blood and other fluids from a human body. California law requires tissue banks to have a current and valid tissue bank license from CDPH. The law includes exemptions for certain procedures, but not the storage or distribution of pasteurized human milk. There are two milk banks that meet the state’s definition of a mothers’ milk bank: Mothers’ Milk Bank in San Jose, founded in 1974, and the UC Health Milk Bank, which was founded in 2020. The UC Health Milk Bank is required to hold a valid tissue bank license to operate, whereas the Mothers’ Milk Bank in San Jose is exempt because it was first licensed before 1995.
The author contends hospitals that are only storing and distributing the pasteurized donor milk product should not be required to have a tissue bank license. California exempts hospitals from obtaining a tissue bank license for the purpose of collecting, processing, storing or distributing human milk collected from a mother exclusively for her own child. Hospitals follow the same safety protocols for storing and distributing pasteurized DHM as a mother’s own milk. This bill exempts the storage or distribution of DHM in a hospital from tissue bank licensure. The author states that only two other states besides California – New York and Illinois – require a tissue bank license for DHM.
- Prevented Disease and Hospital Stays. CHBRP estimates this bill will result in a slight reduction of about 0.62 cases per year in the average incidence of necrotizing enterocolitis (NEC), which is one of the of the main causes of morbidity and mortality among very low birthweight infants. CHBRP also projects a slight reduction in incidence of bronchopulmonary dysplasia (BPD), the most prevalent cause of serious morbidity among preterm infants, of about 1.75 cases per year. NEC and BPD are often fatal, and infants who survive often face serious lifelong consequences, including cerebral palsy, growth and development challenges, and academic difficulties. CHBRP projects corresponding reductions in hospital stays of 18 days for medically treated NEC, 50 days for surgically treated NEC, and 26 days for BPD. CHBRP states these estimates are supported by clear and convincing evidence that DHM is medically effective in preventing NEC and BPD in preterm infants, combined with an estimated 1% increase in utilization of DHM. CHBRP projects this bill would lead to universal access to DHM in California, which could reduce disparities in receipt of DHM for infants at a smaller hospital.
Analysis Prepared by: Allegra Kim / APPR. / (916) 319-2081
Date of Hearing: April 23, 2024
ASSEMBLY COMMITTEE ON HEALTH
Mia Bonta, Chair
ABPCA Bill Id:AB 3059
Author:((Weber) – As Amended Ver:March 11, 2024
SUBJECT: Human milk.
SUMMARY: Requires a health plan contract or insurance policy, as specified, to cover the same health benefits for human milk and human milk derivatives covered under the Medi-Cal program as of 1988. Exempts from tissue bank licensure, the storage or distribution of pasteurized human milk that was obtained from a mothers’ milk bank, as defined, by a general acute care hospital (GACH).
EXISTING LAW:
- Establishes the Department of Managed Health Care (DMHC) to regulate health plans under the Knox-Keene Health Care Service Plan Act of 1975 and the California Department of Insurance to regulate health insurers. [Health and Safety Code (HSC) § 1340, et seq., and (Insurance Code (INS) § 106, et seq.]
- Establishes as California's essential health benefits (EHBs) benchmark under the Patient Protection and Affordable Care Act (ACA), the Kaiser Small Group Health Maintenance Organization, existing California health insurance mandates, and the ten ACA mandated benefits, including maternity services. [HSC § 1367.005 and INS § 10112.27]
- Defines “basic health care services” as all of the following:
- Physician services, including consultation and referral;
- Hospital inpatient services and ambulatory care services;
- Diagnostic laboratory and therapeutic radiologic services;
- Home health services;
- Preventive health services;
- Emergency health care services; and,
- Hospice care, as specified. [HSC § 1345]
- Establishes the Medi-Cal program, administered by the Department of Health Care Services (DHCS), under which low-income individuals are eligible for medical coverage. [Welfare and Institutions Code (WIC) § 14000, et seq.] Establishes a schedule of benefits under the Medi-Cal program, which includes benefits required under federal law and benefits provided at state option but for which federal financial participation is available. [WIC §14132]
- Requires human milk and human milk derivatives supplied by a mothers’ milk bank for human consumption as a covered service under the Medi-Cal benefits program. Defines mothers’ milk bank as any person, firm, or corporation which engages in the not-for-profit procurement, processing, storage, distribution, or use of human milk, contributed by volunteer donors, in compliance with standards prescribed by the Human Milk Banking Association of North America (HMBANA). [WIC § 14132.34]
- Licenses and regulates health facilities by the Department of Public Health (DPH), including GACHs. [HSC §1250, et seq.]
- Requires a hospital that collects, processes, stores, or distributes human milk collected from a mother exclusively for her own child to comply with the most current standards established for the collection, processing, storage, or distribution of human milk by the HMBANA until or unless DPH approves alternative standards. Requires DPH to assess hospital processes for collecting, processing, storing, or distributing human milk pursuant to its current practice, as required. Does not apply to any hospital that collects, processes, stores, or distributes milk from human milk banks or other outside sources. [HSC § 1648]
- Requires every tissue bank operating in California on or after July 1, 1992, to have a current and valid tissue bank license issued or renewed by DPH. Exempts some of the following:
- The collection, processing, storage, or distribution of human whole blood or its derivatives by blood banks licensed, or any person exempt from licensure, as specified;
- The collection, processing, storage, or distribution of tissue for autopsy, biopsy, training, education, or for other medical or scientific research or investigation, when transplantation of the tissue is not intended or reasonably foreseeable;
- The collection of tissue by an individual physician and surgeon from their patient or the implantation of tissue by an individual physician and surgeon into their patient. Prohibits this exemption from being interpreted to apply to any processing or storage of the tissue, except for the processing and storage of semen by an individual physician and surgeon when the semen was collected by that physician and surgeon from a semen donor or obtained by that physician and surgeon from a tissue bank licensed under this chapter
- The collection, processing, storage, or distribution of fetal tissue or tissue derived from a human embryo or fetus; and,
- The storage of a human cell, tissue, or cellular- or tissue-based product, as defined by the federal Food and Drug Administration (FDA), that is either a medical device approved of the Federal Food, Drug, and Cosmetic Act or that is a biologic product approved under federal law by a licensed physician or podiatrist acting within the scope and authority of their license and practicing in a lawful practice setting.
FISCAL EFFECT: Unknown. This bill has not yet been analyzed by a fiscal committee.
COMMENTS:
- PURPOSE OF THIS BILL. According to the author, addressing disparities in health care means looking at access to life-saving nutrition. The mortality rate for Black infants is three times higher than for white infants, so we need to identify what can be done to address staggering disparities within newborn care. Breast milk is the optimal nutrition source for vulnerable babies, but approximately 12% of neonatal intensive care units in California do not use donor milk. Donor milk is a covered benefit under Medi-Cal, but not under commercial plans. This bill will ensure parity and make it clear that donor milk is a covered health benefit for all babies that have a medical necessity. The author concludes that this bill will pave the way for better health outcomes for all vulnerable babies in California.
- BACKGROUND. The American Academy of Pediatrics (AAP) recommends exclusive feeding with human milk for the first six months of life, with the continuation of feeding for 1 year or longer as mutually desired by mother and infant. In addition, the AAP recommends that when mother’s own milk is not available that donor human milk (DHM) be provided to all preterm and low-birthweight. DHM is provided through human milk banks that collect DHM, screen it for disease, pasteurize it, and freeze it for distribution to hospitals for use in the neonatal intensive care unit (NICU) setting. Necrotizing Enterocolitis (NEC) is a severe disease of the intestinal tract and is one of the main causes of morbidity and mortality among very low–birthweight (VLBW) infants.
- Tissue bank requirements. All California hospitals that collect, process, store, or distribute human milk collected from a mother exclusively for her own child must follow HMBANA standards. DPH requires all hospitals that store DHM to hold a tissue bank license. California law defines a tissue bank as a place, establishment, or institution that collects, processes, stores, or distributes tissue for transplantation into human beings. Transplantation is defined as the act or process of transferring tissue, including by ingestion, from a donor to the body of the donor or another human being. Tissue is defined as a human, human cell, group of cells, including the cornea, sclera, or vitreous humor and other segments of, or the whole eye, bones, skin, arteries, sperm, oocytes, embryos, blood, other fluids, and any other portion of a human body. California requires tissue banks operating in California on or after July 1, 1992, to have a current and valid tissue bank license from DPH. The law includes exemptions for certain procedures; however, the storage or distribution of pasteurized human milk is not among them. California milk banks that meet the state’s statutory definition of a mothers’ milk bank that applied for a tissue bank license before January 1, 1995, are exempt from the application and annual renewal fee for a tissue bank license. There are two milk banks that meet the state’s definition of a mothers’ milk bank: Mothers’ Milk Bank in San Jose was founded in 1974, and the University of California (UC) Health Milk Bank was founded in 2020. The UC Health Milk Bank is required to hold a valid tissue bank license to operate, whereas the Mothers’ Milk Bank in San Jose is exempt.
According to the author, milk banks that collect and process unpasteurized milk should have a tissue bank license, while hospitals that are only storing and distributing the pasteurized donor milk product should not. California currently exempts hospitals from obtaining a tissue bank license for the purpose of collecting, processing, storing or distributing human milk collected from a mother exclusively for her own child. Hospitals follow the same safety protocols for storing and distributing pasteurized DHM as a mother’s own milk. This bill exempts the storage or distribution of DHM in a GACH from tissue bank licensure. The author states that only two other states besides California require a tissue bank license- New York and Illinois.
- Medi-Cal coverage of donor milk. Since 1998, California law has required the state’s Medi-Cal program to provide coverage for DHM and human milk derivatives supplied by a mothers’ milk bank for human consumption. Although the law does not define “human milk,” “human milk derivatives,” or details on coverage requirements, DHCS published a policy letter highlighting the importance of breastfeeding for mothers and infants. The policy letter further specified that the timely provision of human milk must be covered if “a mother is unable to breastfeed due to medical reasons, and the infant cannot tolerate or has medical contraindications to the use of any formula, including elemental formulas.” In a May 2023 billing code update, DHCS described Medi-Cal eligibility and noted that mother and infant must have one or more of the following conditions:
- A mother is unable to breast feed due to medical conditions;
- The infant cannot tolerate or has medical contraindications to using formulas including elemental formulas;
- The infant is born at a VLBW (less than1500 g) and very premature (less than 32 weeks gestation);
- Gastrointestinal anomaly, metabolic/digestive disorder, or recovery from intestinal surgery when digestive needs require additional support;
- Diagnosed with failure to thrive (not appropriately gaining weight/growing);
- Formula intolerance, with documented feeding difficulty or weight loss;
- Infant hypoglycemia (low blood sugar); congenital heart disease, pre or post organ transplant;
- Other serious health conditions when the use of banked DHM is medically necessary and supports the treatment and recovery of the infant; and,
- The mother’s milk must be contraindicated, unavailable (due to medical or psychological condition), or available but lacking in quantity or quality to meet the infant’s needs.
- Medi-Cal coverage of donor milk. Since 1998, California law has required the state’s Medi-Cal program to provide coverage for DHM and human milk derivatives supplied by a mothers’ milk bank for human consumption. Although the law does not define “human milk,” “human milk derivatives,” or details on coverage requirements, DHCS published a policy letter highlighting the importance of breastfeeding for mothers and infants. The policy letter further specified that the timely provision of human milk must be covered if “a mother is unable to breastfeed due to medical reasons, and the infant cannot tolerate or has medical contraindications to the use of any formula, including elemental formulas.” In a May 2023 billing code update, DHCS described Medi-Cal eligibility and noted that mother and infant must have one or more of the following conditions:
DHCS further clarified that authorized providers who can prescribe pasteurized DHM are physicians and advance practice nurses (Nurse Practitioners, Clinical Nurse Specialists, Certified Nurse Midwives or Physician Assistants) and may include state licensed nutritionists or registered dieticians under a physician’s supervision. Prescriptions must show the amount and frequency of the feedings, three ounces per unit, 35 ounces per day only good for 30 days. Coverage may be up to 12 months of age as is medically necessary and appropriate. Human milk banks must be accredited by the HMBANA, a nonprofit professional association of milk banks. HMBANA issues safety guidelines on processed DHM for member banks.
- California Health Benefits Review Program (CHBRP) analysis. AB 1996 (Thomson), Chapter 795, Statutes of 2002, requests the University of California to assess legislation proposing a mandated benefit or service and prepare a written analysis with relevant data on the medical, economic, and public health impacts of proposed health plan and health insurance benefit mandate legislation. CHBRP was created in response to AB 1996. SB 125 (Hernandez), Chapter 9, Statutes of 2015, added an impact assessment on EHBs, and legislation that impacts health insurance benefit designs, cost sharing, premiums, and other health insurance topics. CHBRP’s analysis of this bill includes the following:
- Assumptions. This bill would affect coverage of two health services: DHM and human milk-derived fortifiers (HMF). At baseline, CHBRP estimates that 39.13% of enrollees with health insurance subject to this bill have coverage for DHM and HMF. Postmandate, CHBRP estimates that 100% of enrollees with health insurance subject to this bill would have coverage for these benefits.
- Impact on expenditures. In 2025, this bill would result in, approximately, an additional $9,668,000 (0.00006%) in total net annual expenditures. This is inclusive of an approximate $8.6 million shift in expenses for DHM and HMF from providers (hospitals) to health insurance subject to this bill, and cost offsets due to an estimated increase in prevented cases of NEC and Bronchopulmanary Dysplasia (BPD). CHBRP estimates this bill would result in an additional 35 enrollees (1%) utilizing DHM and an additional 11 enrollees utilizing HMF. In the first year postmandate, CHBRP estimates this bill would lead to universal access to DHM in California through the removal of requirements for hospitals to be licensed as a tissue bank in order to provide DHM to patients, and that there would be a reduction in the average number of NEC and BPD cases of 0.62 and 1.75 cases per year, respectively, as well as a corresponding reduction in length of hospital stay (18 days for medically treated NEC; 50 days for surgically-treated NEC; 26 days for BPD).
- Premiums for enrollees in individual plans purchased through Covered California would increase by a total of $1,307,000 in annual expenditures, a 0.0083% increase.
- Medi-Cal. At baseline, Medi-Cal beneficiaries in DMHC-regulated plans have 100% coverage for human milk and human milk derivatives. In DMHC-regulated Medi-Cal plans, total premiums would decrease by $36,000 (0.0001%).
- CalPERS. For enrollees associated with the California Public Enrollees’ Retirement System (CalPERS) in DMHC-regulated plans, premiums would increase by 0.0079% ($0.0621 per member per month, or $553,000 total increase in expenditures).
- Number of Uninsured in California. CHBRP estimates this bill would have no measurable impact on the number of uninsured persons.
- EHBs. In California, nongrandfathered individual and small-group health insurance is generally required to cover EHBs. According to CHBRP, this bill would not appear to exceed the definition of EHBs in California. Washington is currently pursuing a new EHB benchmark plan that would include DHM for inpatient use for infants and parents that meet certain criteria. Washington requires any update to the state EHB benchmark plan to include coverage for DHM.
- Medical effectiveness. CHBRP found clear and convincing evidence that DHM is more effective than preterm formula in the prevention of NEC and BPD in preterm infants. CHBRP found limited evidence that DHM is not as effective as preterm formula for weight gain, and a preponderance of evidence that DHM is no more effective than preterm formula for the prevention of late-onset sepsis in preterm infants. Additionally, findings were inconclusive regarding the effectiveness of DHM versus bovine milk on outcomes for preterm infants.
- Utilization. Inpatient utilization of DHM and HMF At baseline, CHBRP estimated that 3,471 enrollees, or 99% of VLBW and very preterm infants in California NICUs, utilize DHM in the inpatient setting. Postmandate, CHBRP estimated that 3,507, or 100%, of medically eligible enrollees would utilize DHM in the inpatient setting, an increase of 1% or 35 infants. At baseline, CHBRP estimated that 1,041, or 30%, of medically eligible enrollees utilize HMF in the inpatient setting. Postmandate, CHBRP estimated that 1,052, or 30%, of medically eligible enrollees would utilize HMF in the inpatient setting, an increase of 1% or 11 infants. At baseline, CHBRP estimates limited use of DHM and HMF in the outpatient setting due to medical necessity guidelines and utilization management approaches such as prior authorization. While coverage for DHM and HMF would increase to 100% postmandate, it is important to note that benefit coverage does not equal utilization. CHBRP assumed continued limited use of DHM in the outpatient setting postmandate due to the continued use of medical necessity guidelines and utilization management approaches and to access barriers such as availability of the local supply, access to a local milk bank, and the requirement of a prescription from a physician.
- Public health. In the first year postmandate, CHBRP estimates that there would be a reduction in the average number of NEC and BPD cases per year, respectively, as well as a corresponding reduction in length of hospital stay (18 days for medically-treated NEC; 50 days for surgically-treated NEC; 26 days for BPD). This estimate is supported by clear and convincing evidence that DHM is medically effective in preventing NEC and BPD in preterm infants and an estimated increase in utilization (1%) of DHM. CHBRP estimates this bill would lead to universal access to DHM in California through the removal of requirements for hospitals to be licensed as a tissue bank in order to provide DHM to their patients and through reimbursement of these treatments. This could reduce disparities in receipt of DHM between infants with an inpatient stay at a smaller hospital.
- Long-term impacts. In this bill, CHBRP assumes a 1% change in utilization of DHM, which would lead to a reduction in the average number of cases of NEC and BPD over time. As both NEC and BPD are conditions that leave survivors with long-term significant morbidities including cerebral palsy, growth and development challenges, and academic difficulties, the prevention of these conditions could have significant long-term consequences both for the infants and their family and caregivers.
- Assumptions. This bill would affect coverage of two health services: DHM and human milk-derived fortifiers (HMF). At baseline, CHBRP estimates that 39.13% of enrollees with health insurance subject to this bill have coverage for DHM and HMF. Postmandate, CHBRP estimates that 100% of enrollees with health insurance subject to this bill would have coverage for these benefits.
- California Health Benefits Review Program (CHBRP) analysis. AB 1996 (Thomson), Chapter 795, Statutes of 2002, requests the University of California to assess legislation proposing a mandated benefit or service and prepare a written analysis with relevant data on the medical, economic, and public health impacts of proposed health plan and health insurance benefit mandate legislation. CHBRP was created in response to AB 1996. SB 125 (Hernandez), Chapter 9, Statutes of 2015, added an impact assessment on EHBs, and legislation that impacts health insurance benefit designs, cost sharing, premiums, and other health insurance topics. CHBRP’s analysis of this bill includes the following:
- SUPPORT. The UC, sponsor of this bill, writes that DHM has been used for decades to feed premature infants when their own parents’ milk is not sufficient or cannot be used. DHM is used in the NICU to support the health and increase the survival of very low birth weight infants; it has been shown to reduce the incidence of a devastating bowel disease, known as NEC, compared to infant milk formula. Studies have shown that five to ten percent of VLBW babies develop NEC, which disproportionally impacts infants of color. The incidence of NEC is around 60% higher for Hispanic and Black infants when compared to white infants and can be reduced with adequate access to DHM. Expanding access to DHM will help close racial disparities in infant care. This bill would also address a challenge to establishing a DHM program in the requirement that hospitals obtain a tissue bank license to distribute the pasteurized donor milk. Under current law, the milk bank holds a tissue bank license and pasteurizes the milk, thus killing any live cells that can transmit disease. The DHM that arrives at hospitals no longer contains living cells, is ingested and should not be treated the same as tissues and organs. About 12% of NICUs in California do not use DHM, this bill will address this regulatory barrier by exempting hospitals from having to obtain a tissue bank license in order to distribute donor milk to infants in the NICU, setting California on a path of achieving 100% DHM usage in our NICUs.
- SUPPORT IF AMENDED. Prolacta Bioscience writes that it manufactures a first-of-its kind, 100% human milk-derived nutritional product used in NICUs around the country, including across California. Prolacta’s products are used to fortify the diets of vulnerable extremely premature infants and have been clinically shown to decrease instances of complications such as NEC. As a human milk bank, Prolacta complies with all tissue banking regulations in California, holds licenses related to human milk banking in several other states, including Maryland, New York, and Pennsylvania, and is registered as an exempt infant formula manufacturer with the FDA. This bill would not cover Prolacta’s DHM products due to relying on outdated language from the 1988 Medi-Cal coverage. Unfortunately, such language was drafted prior to the development of California’s tissue banking regulations and the ensuing development of other human milk banks in California, such as Prolacta. As such, the reimbursement would only apply to so-called “mothers milk banks” who are dues-paying members of the HMBANA, a trade group of milk banks. By inadvertently creating this monopoly, this bill would be closing out other participants, including local companies like Prolacta, who create life-saving products and have long complied with California’s tissue banking regulations. In addition, this bill would clarify that the state’s tissue banking regulations do not apply to “(t)he storage or distribution of pasteurized human milk that was obtained from a mothers’ milk bank, as defined in Section 14132.34 of the Welfare and Institutions Code, by a general acute care hospital.” At present, any hospital that provides DHM or other DHM products must obtain a tissue banking license, even if they are simply providing donor milk to patients. As written, this bill would remove that requirement, but only for hospitals that obtain milk from a mother’s milk bank. If the Legislature believes the tissue bank license is too onerous for hospitals, it should apply the exemption uniformly to milk procured from all licensed tissue banks, not an arbitrary subset.
- OPPOSITION. The California Association of Health Plans (CAHP), the Association of California Life and Health Insurance Companies (ACLHIC), and America’s Health Insurance Plans (AHIP) oppose mandates for health plans and insurers to cover specific services, as well as bills that eliminate cost sharing and limit utilization management, which have similar cost impacts as coverage mandates. Moreover, they will increase costs, reduce choice and competition, and further incent some employers and individuals to avoid state regulation by seeking alternative coverage options. These bills will lead to higher premiums, harming affordability and access for small businesses and individual market consumers. CAHP, ACLHIC, and AHIP write that state mandates increase costs of coverage, especially for families who buy coverage without subsidies, small business owners who cannot or do not wish to self-insure, and California taxpayers who foot the bill for the state’s share of those mandates.
- RELATED LEGISLATION.
- AB 1926 (Connolly) requires health plan contracts or disability insurance policies to provide coverage for formulas, as defined, for the treatment of chronic digestive diseases and inherited metabolic disorders, as specified. AB 1926 is pending in Assembly Appropriations Committee.
- AB 2914 (Bonta) and SB 1290 (Roth) expresses the intent of the Legislature to review California’s EHB benchmark plan and establish a new benchmark plan for the 2027 plan year. Limits the applicability of the current benchmark plan benefits to plan years on or before the 2027 plan year. AB 2914 is pending in Assembly Health Committee. SB 1290 is pending in Senate Appropriations Committee.
- PREVIOUS LEGISLATION. SB 1316 (Wolk) of 2016 would have required DPH to adopt rules and regulation based substantially on HMBANA guidelines, governing a licensed tissue bank that collects, processes, stores, or distributes human milk. SB 1316 was held in the Senate Appropriations Committee.
REGISTERED SUPPORT / OPPOSITION:
Support
University of California (sponsor)
American Academy of Pediatrics, California
American College of Obstetricians and Gynecologists District IX
BreastfeedLA
California Association of Public Hospitals & Health Systems
California Association of Women's Health, Obstetric and Neonatal Nurses
California Hospital Association
California Life Sciences
California Medical Association
California WIC Association
Children's Specialty Care Coalition
County of Santa Clara
Human Milk Banking Association of North America
Human Milk Connection
Mothers' Milk Bank
UC San Diego's Human Milk Institute
Opposition
America's Health Insurance Plans (AHIP)
Association of California Life & Health Insurance Companies
California Association of Health Plans
Analysis Prepared by: Kristene Mapile / HEALTH / (916) 319-2097
Discussed in Hearing
Assembly Floor
Senate Floor
Senate Standing Committee on Appropriations
Senate Standing Committee on Health
Assembly Floor
Assembly Standing Committee on Health
Assembly Standing Committee on Health
Bill Author
Bill Co-Author(s):